The Recent History of Tumour Necrosis Factor (TNF) by Zarros A et al.
THE RECENT HISTORY OF  
TUMOUR NECROSIS FACTOR (TNF)
The transcript of a Witness Seminar held by the History  
of Modern Biomedicine Research Group, Queen Mary  
University of London, on 14 July 2015
Edited by A Zarros, E M Jones, and E M Tansey
Volume 60 2016
©The Trustee of the Wellcome Trust, London, 2016
First published by Queen Mary University of London, 2016
The History of Modern Biomedicine Research Group is funded by the Wellcome Trust, which is 
a registered charity, no. 210183.
ISBN 978 1 91019 5208
All volumes are freely available online at www.histmodbiomed.org
Please cite as: Zarros A, Jones E M, Tansey E M. (eds) (2016) The Recent History of Tumour 
Necrosis Factor (TNF). Wellcome Witnesses to Contemporary Medicine, vol. 60. London: Queen 
Mary University of London.
CONTENTS
What is a Witness Seminar?  v
Acknowledgements  
E M Tansey and A Zarros vii
Illustrations and credits ix
Abbreviations  xi
Introduction 
Professor Jon Cohen xv
Transcript 
Edited by A Zarros, E M Jones, and E M Tansey 1
Appendix 1 
Timeline of important events in the history of TNF 73
Appendix 2 
Simplified overview of the main biological actions  
of TNF in rheumatoid arthritis 75
Appendix 3 
Overview of TNF inhibitors mentioned in the  





Witness Seminars: Meetings and publications 111

v
WHAT IS A WITNESS SEMINAR?
The Witness Seminar is a specialized form of oral history, where several 
individuals associated with a particular set of circumstances or events are invited 
to meet together to discuss, debate, and agree or disagree about their memories. 
The meeting is recorded, transcribed, and edited for publication. 
This format was first devised and used by the Wellcome Trust’s History of 
Twentieth Century Medicine Group in 1993 to address issues associated with 
the discovery of monoclonal antibodies. We developed this approach after 
holding a conventional seminar, given by a medical historian, on the discovery 
of interferon. Many members of the invited audience were scientists or others 
involved in that work, and the detailed and revealing discussion session 
afterwards alerted us to the importance of recording ‘communal’ eyewitness 
testimonies. We learned that the Institute for Contemporary British History 
held meetings to examine modern political, diplomatic, and economic history, 
which they called Witness Seminars, and this seemed a suitable title for us to 
use also. 
The unexpected success of our first Witness Seminar, as assessed by the 
willingness of the participants to attend, speak frankly, agree and disagree, and 
also by many requests for its transcript, encouraged us to develop the Witness 
Seminar model into a full programme, and since then more than 60 meetings 
have been held and published on a wide array of biomedical topics.1 These 
seminars have proved an ideal way to bring together clinicians, scientists, and 
others interested in contemporary medical history to share their memories. We 
are not seeking a consensus, but are providing the opportunity to hear an array 
of voices, many little known, of individuals who were ‘there at the time’ and 
thus able to question, ratify, or disagree with others’ accounts – a form of open 
peer-review. The material records of the meeting also create archival sources for 
present and future use.
The History of Twentieth Century Medicine Group became a part of the 
Wellcome Trust’s Centre for the History of Medicine at UCL in October 
2000 and remained so until September 2010. It has been part of the School 
of History, Queen Mary University of London, since October 2010, as the 
History of Modern Biomedicine Research Group, which the Wellcome Trust 
1  See pages 111–117 for a full list of Witness Seminars held, details of the published volumes, and other 
related publications.
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funds principally under a Strategic Award entitled ‘The Makers of Modern 
Biomedicine’. The Witness Seminar format continues to be a major part of that 
programme, although now the subjects are largely focused on areas of strategic 
importance to the Wellcome Trust, including the neurosciences, clinical 
genetics, and medical technology.2
Once an appropriate topic has been agreed, usually after discussion with 
a specialist adviser, suitable participants are identified and invited. As the 
organization of the seminar progresses and the participants list is compiled, a 
flexible outline plan for the meeting is devised, with assistance from the meeting’s 
designated chairman/moderator. Each participant is sent an attendance list and 
a copy of this programme before the meeting. Seminars last for about four 
hours; occasionally full-day meetings have been held. After each meeting the 
raw transcript is sent to every participant, each of whom is asked to check his or 
her own contribution and to provide brief biographical details for an appendix. 
The editors incorporate participants’ minor corrections and turn the transcript 
into readable text, with footnotes, appendices, a glossary, and a bibliography. 
Extensive research and liaison with the participants is conducted to produce 
the final script, which is then sent to every contributor for approval and to 
assign copyright to the Wellcome Trust. Copies of the original, and edited, 
transcripts and additional correspondence generated by the editorial process are 
all deposited with the records of each meeting in the Wellcome Library, London 
(archival reference GC/253) and will be available for study.
For all our volumes, we hope that, even if the precise details of the more 
technical sections are not clear to the non-specialist, the sense and significance 
of the events will be understandable to all readers. Our aim is that the volumes 
inform those with a general interest in the history of modern medicine and 
medical science; provide historians with new insights, fresh material for study, 
and further themes for research; and emphasize to the participants that their 
own working lives are of proper and necessary concern to historians.
2  See our Group’s website at www.histmodbiomed.org.
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The idea of doing a Witness Seminar on tumour necrosis factor (TNF) emerged 
during a dinner at the Royal College of Physicians, at which I found myself 
sitting next to Tilli Tansey. The story of TNF can illustrate many of the most 
fascinating and inspiring ideas in science: serendipity, collaboration, tenacity, the 
value of ‘blue skies’ research, basic science being translated into entirely novel 
treatments for patients with a common and disabling disease. On more than one 
occasion I have found myself talking to medical students about the excitement 
of academic medicine as a career and I have turned to the story of TNF, in 
particular the development of anti-TNF, to illustrate my case. It seemed to me 
that the topic was ‘a natural’ for a Witness Seminar, and this volume is the result. 
It was serendipity that led to my own interest in TNF. In the early 1980s I was 
a young and aspiring infectious diseases physician, working on endotoxin 
(lipopolysaccharide, LPS) and the pathogenesis of severe Gram-negative infections. 
For reasons that I do not now recall, I was invited to talk to a meeting of orthopaedic 
surgeons, and I arrived in good time and joined the audience. The speaker before 
me was Fran Balkwill, who has so ably chaired this Witness Seminar. She was 
speaking about a substance which I had never heard of, called ‘osteoclast activating 
factor’, but which turned out to be TNF. I became very excited about the work of 
Beutler and Cerami and the idea that TNF might be a key mediator of septic shock. 
Fran was enormously helpful and put me in touch with Walter Fiers, who very 
generously provided reagents, and I started a programme of work, supported by the 
Wellcome Trust, to take this further. We and others showed that anti-TNF could 
protect experimental animals from septic shock after an LPS challenge and from 
live E. coli infection. The stage seemed set for a potential significant new treatment 
for patients with this life-threatening condition. We were approached by Alistair 
Riddell, then working at Celltech, who wanted to test a monoclonal antibody in 
patients with sepsis, and that led to Andrew Exley (a clinical training fellow in my 
lab) and I publishing a letter in The Lancet in 1990 describing the first clinical use of 
anti-TNF in patients with sepsis.1 As several speakers in the seminar point out, anti-
TNF as a treatment for sepsis sadly proved to be ineffective, but not before tens of 
millions (probably hundreds of millions) of dollars had been spent on a series of large 
clinical trials which investigated a series of different anti-TNF molecules.2 Although 
ultimately unsuccessful, the tale of anti-TNF in sepsis is a good illustration of how 
hard it can be to turn good basic science into a commercially successful therapy. 
1 Exley et al. (1990).
2 See, for example, Abraham et al. (1998), Cohen and Carlet; International Sepsis Trial Study Group 
(1996), Panacek et al. (2004), Reinhart et al. (1996) and Rice et al. (2006).
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It is against that background that this seminar sets out the story of how Tiny 
Maini and Marc Feldmann and their collaborators pushed forward with anti-
TNF, resulting in a truly remarkable and genuinely life-changing treatment 
for patients with rheumatoid arthritis (RA). What comes out very clearly 
from their account is that doing the science was actually in many ways not 
the main challenge. It certainly required the initial intellectual insights to see 
the possibilities, and there were the usual challenges of solving the technical 
problems and of obtaining sufficient funds to be able to carry out the work. 
But some of the most difficult hurdles were in overcoming the practical and 
regulatory hurdles involved in carrying out clinical trials with a reagent (a 
monoclonal antibody) which, at that time, was very unfamiliar territory indeed 
for both clinicians and regulators. Simply manufacturing enough of the material 
to be able to do the study was not straightforward, and there were (at the time, 
entirely reasonable) concerns about potential side-effects such as increasing the 
risk of opportunistic infection. It is to their enormous credit that these obstacles 
were overcome, and millions of patients are indebted to them for their work.
The transcript also illustrates, I think, the hugely important role of clinician 
scientists in bringing about breakthroughs such as this. From their first-hand 
accounts, it is abundantly clear that it was the combination of basic scientists 
working closely alongside academic clinicians, that provided the particular set 
of skills and expertise that could bring an original scientific idea through the 
whole development process from bench to bedside. In today’s National Health 
Service, with its highly structured and rather inflexible training programmes, 
and an intensely competitive academic environment that sets great store on 
basic science, it frequently seems to be the case that bright young clinicians 
must increasingly choose between a career in the research laboratory or training 
as clinical researchers. The inspiring story of anti-TNF for RA should serve as 
a model for young doctors and is one of the most powerful arguments for us 
protecting the species of the clinician scientist.
Professor Jon Cohen
Brighton & Sussex Medical School
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Professor Tilli Tansey:  Good afternoon everyone. I’m Tilli Tansey, the convenor 
of the History of Modern Biomedicine Research Group.1 The purpose of these 
meetings is to get behind the hidden record, get behind the published literature, 
find out what really did happen: what were the key events, who were the key 
people – they may not be the key papers that we all know about. This meeting 
has been planned three times, and, as we were organizing it, very gradually the 
names on the top of your list of the confirmed attendees, migrated down to the 
bottom to apologies received as people found they were unable to come. And at 
one point we did think we would have to cancel, but, having tried three times 
to hold this meeting, we decided to continue.
I’ve had a lot of enthusiastic support from Jon Cohen and Mark Walport, and 
also from Fran Balkwill, to hold this meeting so we are going ahead although we 
are a little depleted today.2 That said, tumour necrosis factor (TNF) is such an 
1 The History of Modern Biomedicine Research Group’s website homepage is: http://www.histmodbiomed.org 
(accessed 11 March 2016).
2 Professor Jonathan (Jon) Cohen, who has written the Introduction to the current Witness Seminar 
transcript, is Emeritus Professor at Brighton & Sussex Medical School (Universities of Brighton and Sussex), 
President of the International Society of Infectious Diseases, Member of the Scientific Advisory Board of 
the Lister Foundation, and a Non-Executive Director of King’s National Health Service (NHS) Foundation 
Trust; http://www.arthritisresearchuk.org/about-us/how-we-are-managed/our-trustees/jon-cohen.aspx 
(accessed 11 March 2016); for more details, see biography on page 84. Professor Sir Mark Walport is the 
Government Chief Scientific Adviser and Head of the Government Office for Science; https://www.gov.uk/
government/people/mark-walport#biography (accessed 11 March 2016).
Figures 1 and 2: Professor Fran Balkwill and Professor Tilli Tansey
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important issue, such an important discovery, and the impact and possibilities 
of TNF are so important we did feel that we should hold a meeting and try 
to produce a volume as soon as we could. An important part of any meeting 
is identifying a suitable chairman: I’m not sure the word ‘chairman’ is right, 
it’s more ‘facilitator’ to try and guide people through general memories and 
discussions. There’s no formal agenda for this meeting, but we have put together 
an outline programme.3 We want people to contribute informally as and when 
they wish to do so. 
And so, without further ado, I’d like to introduce Fran, our chairman; our 
facilitator. Fran needs very little introduction; a very distinguished cancer 
researcher herself, she has been very keen to go ahead with this meeting. She 
is here as a facilitator but also, to a large extent, as a witness and participant 
herself. So Fran, over to you. 
Professor Fran Balkwill:  Thanks, Tilli, and thanks everyone for coming. It’s 
just so great to finally be doing this. This has, as Tilli said, been an idea for a 
long time. My own TNF journey began, I’m not entirely sure whether it was 
1984 or 1985, when I was sitting at my desk at the Imperial Cancer Research 
Fund (ICRF), Lincoln’s Inn Fields, and the phone rang, and somebody I didn’t 
know with a Belgian accent said, ‘Hello, this is Walter Fiers.4 I’ve been reading 
your papers on interferon (IFN). Would you like to work on TNF?’ I had a gut 
feeling he was somebody terribly important so I said, ‘Ooh yes, that sounds 
interesting.’ I rushed up to the library, because I had no idea what TNF was, and, 
ploughing through Index Medicus, I got terribly excited. It really started a career-
long involvement with a molecule that is involved in so many different areas of 
biology, and so this Witness Seminar can be about inflammation, inflammatory 
disease, but also about cancer cells, cell death, and many other things as well.
It’s not my job to steer or say what should happen, so I would just finish this 
introduction by saying TNF is involved in everything, and I was reminded of 
this just last week when we had our tenth anniversary showcase at Barts Cancer 
Institute. Although I hadn’t mentioned TNF very much in my talk, one of my 
ex-clinical fellows, who is now a principal investigator (PI), gave a talk where 
he reminisced quite warmly about his time in my lab doing his PhD.5 During 
3 A draft outline programme was circulated to seminar participants to comment on a month in advance of 
this meeting. Table 1 is the final version of that programme used as a framework for this seminar.
4 For Professor Walter Fiers, see biography on page 86.
5 Dr Peter Szlosarek, Clinical Senior Lecturer at the Barts Cancer Institute.
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Historical context and timeline of events
I  Before 1970s: 
• State of play of rheumatoid arthritis (RA): diagnosis, treatment, and research
• Understanding of autoimmune diseases
II  1970s – mid 1980s:
• Understanding of autoimmune diseases
• Role of cytokines in inflammation, immunity, and cell growth
III  Mid 1980s – early 1990s: 
• Collaboration of Feldmann and Maini to study disease mechanism in RA
• Identification of tumour necrosis factor (TNF) in diseased joints
• Recognition of a potential therapeutic approach
• Experimental, clinical, and commercial collaborations
IV   Early 1990s – c.2000:
• First clinical trials were performed (1992); infliximab from Centocor
• Other companies focusing on TNF-related therapeutics
• Applications for other diseases
V   2000s:
• State of play of RA: diagnosis, treatment, and research
• Understanding of autoimmune diseases
Areas of focus:
• The role of funding and institutional support
• Relations and collaborations between different groups of workers, including 
lab researchers, clinicians, industrial, and funding bodies
• The acceptance and development of new theories
• Translational research from the lab to the clinic, and then to commercial 
production
Table 1: Witness Seminar outline programme
it he’d discovered a molecule called ‘argininosuccinate synthase’ – it’s known as 
‘ASS1’ now – but at the time we all called it ‘ASS’, and we would tease the hell 
out of him. We said, ‘You don’t want to study that boring metabolic gene.’ But, 
in fact, the talk he gave, this total persistence over the last 15 years, where he 
found it was a major TNF-related gene but in other cancer types, again showing 
this ‘yin and yang’ of TNF; it’s actually a tumour suppressant. When you’ve 
got an absence of ASS in the tumour, you can deplete arginine and it actually 
is quite lethal for the cancer. This has now gone with worldwide clinical trials 
of this inhibitory pathway in diseases like mesothelioma. The reason I’m telling 
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this story is not just the fact that TNF is involved in so many areas of biomedical 
science, but he reminded me of how he ended up in my lab. Back in 1988 when 
Peter Szlosarek was doing his A levels, he was in the school library and he started 
reading Scientific American and he came across an article from Lloyd Old on 
TNF.6 Tilli and I now both have a copy of this; you may like to look at it later. 
And it was that, and then doing his medical degree, hearing a talk at the ICRF 
that I gave apparently when he was doing a BSc, and then finding an advert in 
the British Medical Journal for a clinical fellowship working on TNF, that ended 
up all these years later with this story on a drug that targets cancer metabolism.
It was just really nice that because both Tilli and I could go back and find that 
Lloyd Old paper from 1988, so that really sums up TNF for me. I’m just really 
happy everyone is here and I look forward to an interesting afternoon, starting 
with thinking about the pre-1970s. Marc, maybe you would like to start?
Professor Sir Marc Feldmann:  If we are discussing the state of play of rheumatoid 
arthritis (RA) diagnosis, treatment, research pre-1970s, I will do what I’ve often 
done and pass the microphone to my colleague, Tiny. [Laughter]
Professor Sir Ravinder Nath (Tiny) Maini:  Okay, well, so that is really forcing 
the focus on RA.
Balkwill:  To begin with, I think that’s fine. 
Maini:  I’m a clinician but also a laboratory scientist, and I began training as 
a rheumatologist in 1966, when I joined a group of that small speciality and 
realized that as an undergraduate I wasn’t taught very well about the scope of 
rheumatic diseases, and that RA was a very interesting and important disease. 
In the 1970s, it really was inadequately treated because there was no known 
significant therapy for it, and the therapeutics that were in the clinic had got 
there more or less by anecdotal evidence. A number of these drugs were routinely 
used by some rheumatologists, but not by others, and rheumatologists by and 
large were very strongly brought up on the ethics of Hippocrates ‘do no harm 
to your patient’.7 And so the instruction I received when I started treating RA 
6 Old (1988). Lloyd John Old (1933–2011) was a leading figure in the field of tumour immunology. From 
1971 to 2011, he served as the Scientific and Medical Director of the Cancer Research Institute (New York); 
http://www.cancerresearch.org/about/lloyd-j-old (accessed 11 March 2016).
7 The phrase is indirectly contained in the Hippocratic Oath and the Hippocratic Corpus; in the latter the 
phrase ‘ἀσκέειν, περὶ τὰ νουσήματα, δύο, ὠφελέειν, ἢ μὴ βλάπτειν’, which can be translated as ‘strive, 
with regard to diseases, for two (things), (namely) to do good or to do no harm’. 
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was to be very cautious with introducing drugs such as gold injections, which 
were used for the treatment of RA, their efficacy having been demonstrated 
in a controlled clinical trial in 1961.8 However, gold was very toxic and it was 
known to cause severe rashes and bone marrow aplasia, renal damage, and so 
on.9 Consequently, its use was, in some quarters, pretty well neglected. 
The big breakthrough, of course, had come with the discovery of cortisone by 
Hench and others in 1948, and what he had demonstrated was a remarkable 
effect of cortisone on patients with RA.10 And, interestingly, the clinic where I 
was attached as senior registrar in West London, was one of the first clinics to 
use cortisone treatment in the UK. And they had gone through a cycle of using 
cortisone and adrenocorticotropic hormone, quite extensively. They had a lot of 
experience with it, and had come to the conclusion that it was a pretty toxic 
8 Research Sub-Committee of the Empire Rheumatism Council (1961); see also note 11.
9 See, for example, Lawrence (1953) and Bogg (1958).
10 See, for example, Hench et al. (1949). Philip Showalter Hench (1896–1965) was awarded the Nobel 
Prize in Physiology or Medicine in 1950, with Edward Calvin Kendall and Tadeus Reichstein ‘for their 
discoveries relating to the hormones of the adrenal cortex, their structure and biological effects’; http://www.
nobelprize.org/nobel_prizes/medicine/laureates/1950/ (accessed 14 March 2016). 
Figure 3: Professor Sir Ravinder Nath (Tiny) Maini
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drug although it was very beneficial. The Empire Rheumatism Council11 had 
conducted trials with cortisone and shown it to be effective, but its side-effects 
were a severe limitation, largely because it was overused.12 So it’s very interesting 
to reflect that, today, synthetic prednisone or its active metabolite, prednisolone, 
are both extensively used by rheumatologists in treating RA in lower doses or for 
induction therapy in higher doses for a very short time. Undoubtedly, it has a 
very important place in initially controlling disease activity and symptoms of RA.
In the 1970s there was essentially a failure in treating RA. It was commonplace 
in our outpatient clinics to see patients in wheelchairs, and half the clinic would 
be occupied by patients in wheelchairs. In those days we had a ward dedicated 
to the inpatient treatment of RA. Well, today, if you go to a rheumatology 
clinic, you won’t see many wheelchairs. The rheumatology ward that we had 
at this hospital and, subsequently, at Charing Cross Hospital, disappeared. All 
patients are now treated as an outpatient and the quality of life they enjoy is 
hugely improved, and we can come back to that in a minute. 
Let me begin with a very small picture of the evolution of the treatment of RA by 
stating that the major clinical trials for treating RA occurred only in the 1980s, 
and the first drug that impressed rheumatologists for its efficacy in a short-term 
clinical trial was methotrexate.13 Methotrexate had been used previously in the 
1950s,14 but again anecdotally and in doses which were thought to be not toxic; 
in other words there were very low doses used intermittently, weekly, compared 
to the doses that we use for treating cancer. Interesting that there is a crossover 
between cancer and RA with this drug treatment, as there is with other anti-
rheumatoid drugs. 
And, of course, other cytotoxic drugs were also used empirically, like azathioprine, 
chlorambucil, and cyclophosphamide.15 All of these drugs were used because of 
their potential at inhibiting cell division, which inhibited the immune response 
11 The Empire Rheumatism Council was founded in 1936. In 1964 it became the ‘Arthritis and Rheumatism 
Council’, while in 1998 it was re-named the ‘Arthritis Research Campaign’. In 2010 the charity became 
‘Arthritis Research UK’. For more details, see http://www.arthritisresearchuk.org/arthritis-information/
arthritis-today-magazine/151-winter-2011/back-to-the-future.aspx (accessed 16 March 2016). 
12 See, for example, Research Sub-Committee of the Empire Rheumatism Council (1957).
13 See, for example, Ward (1985) and Willkens (1985).
14 For methotrexate, see Sir Kenneth Calman’s ‘praise poem’ in volume 30 of the Wellcome Witnesses to 
Twentieth Century Medicine series: Christie and Tansey (2007), pp. 78–81.
15 See, for example, Luqmani, Palmer, and Bacon (1990).
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as well. But the well-controlled clinical trials really weren’t done till the 1980s, 
when other effective drugs emerged, and included not only methotrexate, but 
a drug called ‘salazopyrin’, also known as ‘sulphasalazine’, and gold.16 So those 
were the essential drugs that were implemented in practice in the 1980s. 
Professor Yuti Chernajovsky:  At the time that you just described, what 
was the hypothesis regarding the mechanism of RA? Were people talking of 
autoimmunity at that time already?
Maini:  Yes, I think that the discovery of rheumatoid factor was described in 
1940 by Erik Waaler in Norway.17 Subsequently a test was developed, called 
the ‘Rose–Waaler test’, which was routinely used by rheumatologists, and 
which is a test for immunoglobulin M (IgM) class of the rheumatoid factor; 
an autoantibody directed against determinants in the fragment crystallizable 
(Fc) portion of immunoglobulin G (IgG).18 So RA had joined systemic lupus 
erythematosus (SLE) as an autoimmune disease based on this diagnostic test. 
In the 1960s there was quite a lot of interest in the microscopic histology of the 
joint in RA, and there were seminal papers from many groups, including that of 
Morris Ziff in Texas, also looking at ultrastructural level in the synovium, and 
describing a heavy infiltration with immune cells, predominantly lymphocytes, 
some of them arranged in aggregates or follicles.19 
Balkwill:  Would they be like what we call ‘tertiary lymphoid structures’ now, do 
you think?
Maini:  Two kinds of infiltration were observed: firstly, diffuse infiltration, and 
secondly, a more organized structure. The organized structure tends to occur 
in more chronic disease, but all patients also have massive diffuse lymphocyte 
infiltration, predominantly by T cells of certain subtypes, and by B cells, and, 
of course, by monocytes. 
Balkwill:  So if we stay on the RA theme for a minute, when did the first ideas 
arise about TNF being involved in RA?
16 For the use of salazopyrin in the treatment of RA, see Pullar, Hunter, and Capell (1987).
17 Erik Waaler (1903–1997) was a Norwegian Professor of Pathology at the University of Bergen; for the 
original article describing the discovery of the rheumatoid factor, see Waaler (1940). 
18 The Waaler–Rose test is a serotological test for diagnosing RA that has been based upon the Waaler’s 
1940 test, and was (also) elucidated by Rose et al. (1948), without prior knowledge of his discovery; for a 
more detailed account, see Alexander (1967–1968). 
19 See, for example, Ziff (1965).
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Professor Joachim Kalden:  I was Head of the Department of Internal Medicine 
that specialized in clinical immunology, rheumatology, and haematology at the 
Institute for Clinical Immunology at the University of Erlangen-Nürnberg. 
When I finished my medical studies in Germany in 1965, I had rarely seen 
a patient suffering from any type of rheumatoid disease. The textbooks were 
nearly blank. Rheumatic diseases were treated at this time in spa areas. The 
major medication included gold injection and physiotherapy. Interest in a more 
intensive study in the pathogenesis and the development of new treatment 
principles of rheumatic diseases started at the end of the 1960s/1970s, when quite 
a number of young German academic fellows with an interest in autoimmune 
diseases returned from a long stay abroad. I, for example, spent a couple of years 
at the University of Edinburgh studying autoimmune diseases of the neuro- and 
endocrine systems. With regard to rheumatic diseases, studies centred on SLE 
and, later on, also on RA. By the end of the 1980s, based on studies into the 
pathogenesis of RA, we developed mouse monoclonal antibodies targeting the 
CD4 molecule of T cells;20 the results we obtained in an open label trial with 
a mouse monoclonal antibody were very promising, but later on in placebo-
controlled trials, it became quite clear that targeting the CD4 molecule was not 
the way for an effective intervention into the course of RA. With these negative 
20 CD4: cluster of differentiation 4; a glycoprotein found on the surface of immune cells, helping them to 
communicate with an antigen-presenting cell.
Figure 4: Professor Joachim Kalden
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data, T cells as targets disappeared for a while until a new biologic, abatacept, 
which blocks the interaction between dendritic cells and T cells in RA, was 
nearly as efficacious as blocking TNF alpha (TNFα).
Feldmann:  The work that Tiny and I did began by focusing on cytokines. This 
came about by thinking why was it that most autoimmune disease sites, which 
were infiltrated by lymphocytes and macrophages, had dramatic upregulation 
of human leukocyte antigen – antigen D-related (HLA-DR) molecules. In 
the 1970s, the dominant theme for autoimmunity was its human leukocyte 
antigen (HLA) region linkage, genetically.21 It was found that, essentially, all 
the autoimmune diseases were linked to HLA class II, some of them a little bit 
strangely. SLE was much more a complement linkage – some complement genes 
are in the middle of the HLA region – than actually HLA itself. Autoimmunity, 
that was the key driver for thyroid disease, diabetes, RA, and so on. My 
involvement in autoimmunity dates back to my PhD studies. 
In the modern era, autoimmunity was initially a theoretical construct, proposed 
first by Paul Ehrlich,22 but defined by the work of Sir Frank Macfarlane Burnet;23 
he had been the director of the Walter and Eliza Hall Institute,24 where I did a 
PhD, and so this was something that I was always interested in. Then, when I 
was in London studying immune regulation, the role of HLA-DR molecules 
in presenting antigen, Gian Franco Bottazzo and Deborah Doniach came to 
visit me.25 They were at the Middlesex Hospital in London, I was at University 
College London (UCL); not part of one institution at the time but about 
500 yards apart. They showed me histological pictures of thyroid disease and 
diabetes with dramatically upregulated HLA-DR and were very excited about 
how useful this might be as a marker. They asked me what did I think this 
might mean. Actually, if you are an immunologist, then of course HLA-DR is 
more than a marker – it has a function – it’s important in antigen presentation, 
so my response was fairly clear. This upregulated HLA-DR suggested that 
antigen presentation is locally important, and this discussion, which took place 
21 See, for example, Bodmer (1980) and Gough and Simmonds (2007).
22 For more details on the development of the concept of ‘autoimmunity’, see Silverstein (2001).
23 See, for example, Burnet (1961).
24 The Walter and Eliza Hall Institute (founded in 1915) is an Australian medical research institute; see a 
brief history at http://www.wehi.edu.au/about/history (accessed 21 March 2016).
25 Professor Gian Franco Bottazzo (b. 1946) was the first researcher to recognize that type 1 diabetes was an 
autoimmune disease. For Deborah Doniach (1912–2004), see Tansey et al. (1997) and obituary by Wright (2013).
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probably in late 1982, ended up as a joint publication. It was a hypothesis 
paper in The Lancet with Franco as the first author, but actually I wrote it all 
and I was the last author.26 Basically, what it pointed out was that if antigen 
presentation was upregulated in a local tissue site which naturally expressed 
autoantigens, then because tolerance to self antigens is not locked in, it’s not a 
deletional tolerance, it’s a form of regulation; hence there was an opportunity for 
triggering immune responses. So we published this hypothesis paper in 1983, 
discussing upregulation of HLA-DR, upregulation of antigen presentation, and 
the pathogenesis of autoimmunity. 
That encounter had really started me thinking about autoimmunity, and the 
paper was the primer to try to test that hypothesis. The hypothesis could be 
tested at the cellular level in thyroid disease. I was working with Bottazzo, and 
since thyroid disease is classically treated by surgery, we used autoimmune 
hyperthyroidism specimens as a model in which we got a lot of lymphocytes and 
a lot of epithelial thyroid tissue. We showed, with the help of Jonathan Lamb, a 
postdoc, that T cell clones that recognized peptides could be restimulated both 
by classical, antigen-presenting cells, but also by epithelial cells which expressed 
HLA-DR and had been soaked with the relevant peptides,27 and, subsequently 
with Marco Londei, that the autoimmune disease had autoantigen reactive T 
cells that recognized the endogenous peptides.28 
So from this 1982 discussion came a hypothesis that was, I think, quite 
influential at the time. It led to a whole plethora of transgenic mice producing 
various cytokines locally, and produced by several groups: Nora Sarvetnick was 
the first one. She put IFN gamma (IFN-γ) genes under control of the insulin 
promoter, and this generated autoimmune diabetes as local production of the 
cytokine drove up antigen presentation.29 
Balkwill:  Ah, that’s the link. 
26 Bottazzo et al. (1983).
27 Londei et al. (1984). Professor Jonathan Lamb is now Chair of Immunoregulation in the Division of 
Cell and Molecular Biology, Imperial College London; http://www.imperial.ac.uk/people/jonathan.lamb 
(accessed 21 March 2016).
28 Londei, Bottazzo, and Feldmann (1985). 
29 Sarvetnick et al. (1988). Professor Nora E. Sarvetnick is Director of the Holland Regenerative Medicine 
Program and Professor at the Department of Surgery of the University of Nebraska; http://www.unmc.edu/
surgery/divisions/transplant/faculty/sarvetnick.html (accessed 21 March 2016).
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Feldmann:  The over-produced cytokine could be shown to induce 
autoimmunity. My path went in a different direction: once I knew that the 
cellular immunology in a human autoimmune disease was consistent with this 
hypothesis, my interest was to go back to my medical roots and do something 
therapeutically important, and that couldn’t be done in thyroid disease. The 
treatment of thyroid disease is very simple with very effective and very cheap 
surgery, and therefore the next issue was which autoimmune disease to look at. 
At UCL, in Avrion Mitchison’s group, there had been a visiting rheumatologist, 
Nathan Zvaifler, who came to spend a sabbatical with him, but ended up in 
my tender, loving care.30 I taught him a little bit of immunology and he taught 
me a little bit of rheumatology, so when I thought RA might be a useful disease 
model to continue with this study, to try and work out what mediators might 
be important, I asked him who I should contact. He told me exactly the person: 
Ravinder Maini, two or three miles down the road. I contacted Tiny, and that’s 
essentially how autoimmune mechanistic ideas on HLA regulation linked to 
cytokines moved from infertile ground in thyroiditis to what became a very 
fertile area: RA. 
30 Professor (Nicholas) Avrion Mitchison (b. 1928) is Professor Emeritus and has served as Professor of 
Zoology and Comparative Anatomy at UCL. Nathan Zvaifler (1927–2015) was a Professor of Rheumatology 
at the San Diego School of Medicine, University of California. 
Figure 5: Professor Sir Marc Feldmann
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Maini:  I just want to pick up a point that Marc is making about HLA presentation 
and the importance of T cells. I think that our thinking in the 1980s became 
very strongly entrenched in the model that Marc has outlined, that basically all 
autoimmune disease would turn out to be HLA-dependent antigen-presenting 
diseases. Now the problem in RA was that there wasn’t a well-characterized 
autoantigen, apart from Ig as the antigen for rheumatoid factor, and rheumatoid 
factors, of course, occur in many diseases, such as chronic infections or chronic 
liver disease and are not rheumatoid-specific – any chronic inflammatory disease 
will be accompanied by rheumatoid factor. So there was serious doubt that 
rheumatoid factor was pathogenic, unlike DNA and DNA antibodies, which 
were thought to be the pathogenic molecules in SLE. 
Balkwill:  And that was another reason why RA was a good choice as a model?
Maini:  Yes, indeed. I think Marc will recall that we spent quite a lot of time in 
that initial period of collaboration on studying T cells. In fact, Marco Londei, 
working in Marc’s laboratory, did isolate T cell clones from a rheumatoid joint 
reactive with collagen type II.31 Now, collagen type II was a candidate autoantigen 
for RA proposed by Swedish workers,32 as it is expressed predominantly in the 
cartilage of joints in humans, and could have been the key autoantigen driving 
the immune response. Today, we know that it is only one of the important 
autoantigens, not as ‘native’ collagen but as post-translated citrullinated collagen 
antigen, in a proportion of rheumatoid patients. So today we accept the dogma 
that citrullinated proteins that are expressed at sites of inflammation – amongst 
which the best described ones are citrullinated forms of enolase, vimentin, and 
fibrinogen – are essentially the predominant targets of the immune response 
that give rise not only to corresponding specific T cells, but also to specific IgG 
antibodies. 
When I first started to take an interest in the pathogenesis of RA, there were 
two major findings that were of interest. One was that immune complexes were 
present in the joint,33 and these were characterized as ‘IgG rich’, but it was not 
possible to identify what the antigen component of these complexes was, other 
than that rheumatoid factors self-associated. The second was that patients with 
RA had depressed, delayed-type sensitivity reactions to skin tests. At that time 
31 Londei et al. (1989). Dr Marco Londei is Chief Development Officer at AnaptysBio; http://www.
anaptysbio.com/marco-londei/ (accessed 21 March 2016).
32 Klareskog et al. (1983).
33 For example, see Bourke et al. (1982).
The Recent History of Tumour Necrosis Factor (TNF)
15
it was becoming evident from the work of Barry Bloom and John David that 
delayed-type sensitivity was mediated by T cells and soluble factors such as the 
macrophage migration inhibition factor (MIF).34 
Balkwill:  And presumably things like TNF as well?
Maini:  Well, we didn’t know about TNF at that time but had been informed 
about a cytotoxic factor called ‘lymphotoxin’. I think Jeremy Saklatvala might 
pick that story up about TNF. But MIF was the predominant, soluble factor 
that was described in 1966, I think, Marc, wasn’t it?35 Anyway, MIF was the 
hypothetical soluble mediator of a delayed hypersensitivity reaction that might 
be implicated in the pathogenesis of inflammation observed in RA. But, 
paradoxically, patients with RA were deficient in delayed-type sensitivity skin 
reactions, so there was a competing concept that it may be an immune-deficient 
disease. 
My fellowship at the bench was undertaken with an immunologist, Dudley 
Dumonde, who was one of the pioneers of the cytokine field in London.36 He 
was at St Mary’s and subsequently at the Kennedy Institute of Rheumatology.37 
34 Bloom and Bennett (1966) and David (1966). Professor Barry R. Bloom is Harvard University 
Distinguished Service Professor and Joan L. and Julius H. Jacobson Professor of Public Health at the 
Harvard T. H. Chan School of Public Health; http://www.hsph.harvard.edu/barry-bloom/ (accessed 21 
March 2016). Professor John David is Emeritus Richard Pearson Strong Professor of Tropical Public Health 
at the Harvard T. H. Chan School of Public Health; http://www.hsph.harvard.edu/john-david/ (accessed 21 
March 2016).
35 Bloom and Bennett (1966). 
36 The late Dudley Dumonde was Head of the Immunology Division of the Kennedy Institute from the 
late 1960s to 1977. He pioneered work on soluble factors generated by activated lymphocytes, which acted 
as ‘messenger molecules’ mediating a wide variety of biological activities on cells in their local environment. 
He coined the term ‘lymphokines’ to describe these heterogeneous activities, which in the 1980s became 
characterized as several molecules belonging to the ‘cytokine’ family.
37 The Kennedy Research Institute of Rheumatology was an independent research centre managed 
by The Mathilda and Terence Kennedy Institute of Rheumatology Trust (now ‘The Kennedy Trust for 
Rheumatology Research’) from its foundation in 1996 to 2000. In 2000, the scientific staff of the Research 
Institute were incorporated as a Division in the Faculty of Medicine at Imperial College. In 2011, the 
Kennedy Research Institute of Rheumatology transferred to Oxford University as an autonomous research 
centre within the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences; for 
more details, see http://www.kennedy.ox.ac.uk/about/our-history (accessed 10 June 2016). At Oxford, the 
Kennedy Research Institute of Rheumatology received a substantial grant from the Kennedy Trust for a new 
building, equipment, and staff, and continues to receive financial support originating from royalty income 
on Feldmann and Maini patents on anti-TNF therapy owned by the Trust.
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I actually joined his lab at St Mary’s in London and we worked with soluble 
mediators, and in 1969, with Dudley Dumonde, I published a paper on a factor 
called ‘lymphocyte mitogenic factor’ in Nature.38 He simultaneously published a 
paper on lymphocyte mitogenic factor in mice, which he termed a ‘lymphokine’, 
and this factor also had other activities; in that way, lymphocyte-derived factors 
became known as ‘lymphokines’.39 But soon thereafter, other people working 
with monocytes described similar factors that monocytes were producing, so they 
became known as ‘monokines’, and some of these had chemotactic activity and 
they were called ‘chemokines’. Then, I believe, at an international nomenclature 
meeting, which I’m sure Marc was probably attending, it was decided that we 
should lump all these soluble factors together and call them all ‘cytokines’. 
Associate Professor Richard Williams:  I wanted to expand a little bit on 
what Tiny mentioned. I joined the Kennedy Institute in 1989, and prior 
to then I’d been working on an animal model of RA in which you take 
genetically susceptible mice and immunize them with collagen type II, which 
is the major constituent of cartilage, and they develop an RA-like disease.40 
38 Maini et al. (1969).
39 Dumonde et al. (1969).
40 Courtenay et al. (1980), Williams and Whyte (1989), and Williams, Whyte, and Waldmann (1989).
Figure 6: Associate Professor Richard Williams
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So we had the animal model, coupled with the description of antibodies to 
collagen type II in the sera of patients with RA, as well as the studies by Marco 
Londei in Marc’s lab, who had cloned T cells specific for collagen type II. 
There was this very strong hypothesis that RA was in fact a form of collagen-
induced arthritis. 
I joined the Institute at this stage under the supervision of David Williams41 and 
our role was, in the first place, to look for and identify patients with antibodies 
to collagen type II. As for the results, we identified a small handful of patients 
with antibodies to native collagen type II, so basically the hypothesis was not 
founded. 
Kalden:  As I mentioned before, back in the 1970s and early 1980s, we were 
interested in T cells as a target for immune intervention in RA. The interest 
was based on data coming from patients and from in vitro experiments, as well 
as from experimental animal models. Thus, Frank Emmrich in the Institute 
developed a mouse anti-CD4 monoclonal antibody.42 We did a Phase 1 trial, the 
data was perfect, so we thought we had it.43 Later on, placebo-controlled trials 
demonstrated that targeting CD4 was not the molecule to lead to a significant 
improvement of signs and symptoms.44 But again, as indicated before, after the 
T cells disappeared as a target in RA, they came back with a fusion protein which 
blocks the interaction; something that would lead to a significant improvement 
in the clinical course of RA patients. 
Balkwill:  I think it’s quite good to carry on on the rheumatoid theme for a bit, 
and then come back to the cancer story. My memory from being interested 
in TNF in the cancer field was that then there were some papers where over-
expression of TNF caused RA in mice. So how did the field move from T cells 
to anti-TNF?
41 Dr David (Gareth) Williams was an ARC Senior Research Fellow (1983–1996) at the Kennedy Institute 
of Rheumatology.
42 Emmrich et al. (1991). Professor Kalden noted: ‘when this monoclonal antibody was used in an open 
type Phase 1 trial, 40 to 50% of patients showed an improvement in signs and symptoms with a depletion 
of CD4+ T cells.’ E-mail to Dr Apostolos Zarros, 5 April 2016. For more details, see Horneff et al. (1991). 
Professor Frank Emmrich is Chairman of the Department of Clinical Immunology and Director of the 
Institute of Clinical Immunology at the University of Leipzig; see http://www.ethikrat.org/about-us/
members/frank-emmrich (accessed 21 March 2016). 
43 Horneff et al. (1991).
44 Breedveld (1998) and van der Lubbe et al. (1993).
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Professor Jeremy Saklatvala:  In the 1970s, people became aware that there were 
small proteins made by lymphocytes, monocytes, and macrophages that seemed 
to be hormones of inflammation and immunity. Tiny has mentioned their 
collective terms: ‘lymphokines’ and ‘monokines’ – lumped together they were 
called ‘cytokines’. I was one of a number of people who were trying to isolate 
these mysterious proteins. Were there two or three of them, or a hundred of 
them, or what? I was a rheumatologist by training, but had moved into basic 
research because I was interested in biochemical mechanisms of tissue destruction 
in inflammation, which was the major clinical problem in RA and other similar 
inflammatory diseases. I was working at a lab in Cambridge called the ‘Strangeways 
Research Laboratory’ with Dame Honor Fell, John Dingle, Alan Barrett, and John 
Reynolds.45 They were among the first people to define the proteolytic enzymes 
that controlled the turnover of the proteins that formed the extracellular matrix of 
connective tissues; these were the collagens and proteoglycans. 
I joined the Strangeways lab in 1976 when Honor Fell had just shown an 
interesting activity that the joint lining tissue – the synovial membrane – 
expressed in culture.46 This was due to a substance that stimulated cartilage 
45 For more details on the Strangeways Research Laboratory (founded in 1905, Cambridge) and the research 
work undertaken at the time, see Dingle (1979). 
46 Fell et al. (1976). 
Figure 7: Professor Jeremy Saklatvala
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to reabsorb by causing the chondrocytes to dissolve their extracellular matrix. 
Subsequently, we found it had a similar effect on bone. We thought this could 
be a mediator made in inflammation, so a big effort was made to purify it. 
The active protein came to be called ‘interleukin-1’ (IL-1), though at that time 
we had given it another name, ‘catabolin’, because it caused catabolism of the 
extracellular matrix. That was one of the strands of research leading to the 
defining of various biological activities of IL-1.
Historically, the oldest of these activities was that of ‘endogenous pyrogen’, a 
substance from leukocytes that caused fever. Paul Beeson in 1948 was the first 
person to identify this.47 But protein purification techniques were not good 
enough to purify these very low abundance proteins, which worked at very low 
concentrations, until the late 1970s and early 1980s. Molecular cloning didn’t 
really become practicable until the early-to-mid 1980s. Therefore, there was a 
long wait until these molecules were obtained in useful amounts. So our protein 
that was causing the tissue resorption was a molecule that had come to have 
several names, ‘endogenous pyrogen’ being the first. That became ‘IL-1’.
Initially, there was confusion because two different molecules, having identical 
biological properties, had actually been isolated. One became ‘IL-1 alpha’ (IL-
1α), and the other became ‘IL-1 beta’ (IL-1β). They were only about 20 per 
cent homologous in their amino acid sequence, but they did have a common 
receptor so that explained their common properties. So we were all very excited 
about IL-1 as a driver of tissue resorption, and as a very potent pyrogen. We 
had isolated a molecule that caused cartilage destruction when injected into a 
rabbit knee, but if you injected a few nanograms of it into a rabbit brain, the 
animal started shivering and its body temperature was rapidly elevated. And so 
we thought, ‘Ah, this is really important stuff.’ That takes us to about 1984/85.
In 1985, I was in Boston visiting Charles Dinarello, a fever physiologist and 
one of the pioneers of IL-1.48 He told me a very interesting story. He asked if I 
had heard of Coley’s toxin and TNF: Coley had claimed that some microbial 
toxins caused regression of cancers.49 Later investigators had defined a substance 
that caused tumour cell necrosis in serum of animals injected with bacteria. 
47 Beeson (1948). 
48 For Professor Charles Dinarello, see biography on page 84. 
49 See, for example, Coley (1893). A useful short account of Coley’s mixed toxins is provided by Balkwill 
(2009). Moreover, a timeline of important events in the history of TNF is provided in Appendix 1.
The Recent History of Tumour Necrosis Factor (TNF)
20
Charles told me that Genentech,50 among other biotechnology companies, had 
prepared this cytokine in large quantities to try as a cancer treatment. However, 
in a Phase 1 clinical trial in patients with cancer, the recombinant TNF had 
caused high fever.51
Balkwill:  I think one died, actually. 
Saklatvala:  Because the protein was made in bacteria, Genentech thought they 
might not have got rid of all the endotoxin and traces of this were causing fever, 
so they screened their preparations again for endotoxin. They thought they’d 
eliminated it, so why are these patients getting so sick? Charles was a leading 
fever physiologist and cytokinologist, so they sent the TNF to him, asking: ‘Do 
you think this TNF is a pyrogen, or are there pyrogenic microbial contaminants 
in it?’ So Charles did a number of experiments, mainly on mice, and came to 
the conclusion that TNF was a pyrogen in its own right, and similar to IL-1.52 
He gave this molecule to other people investigating various different activities 
of IL-1, asking: ‘Does TNF have effects similar to IL-1? Is this tumour-killing 
molecule really another inflammatory hormone like IL-1?’ Generally, we found 
that TNF did all the things that IL-1 would do, but you needed about ten times 
as much of it to cause the same effect. 
Balkwill:  Was it because you were using recombinant human TNF in the mice? 
Because I remember that human TNF wasn’t as toxic to mice as mouse TNF. 
Saklatvala:  I don’t know. I think it is a genuine difference, possibly due to 
difference in affinity for the receptors. 
Another strand to the story, although I wasn’t personally involved in this, was 
that TNF was also discovered as ‘cachectin’ by Bruce Beutler and Tony Cerami 
at the Rockefeller University.53 Their protein was responsible for the general 
muscle wasting or cachexia of cancer. They did some experiments with Jean-
50 Genentech (founded in 1976) is a biotechnology company that is now a part of the Roche Group; see 
http://www.gene.com/media/company-information/chronology (accessed 21 March 2016). 
51 Creagan et al. (1988) and Selby et al. (1987). 
52 Dinarello et al. (1986). 
53 Beutler and Cerami (1986). Bruce A. Beutler (b. 1957) was awarded one half of the 2011 Nobel Prize in 
Physiology or Medicine, jointly with Jules A. Hoffmann, for ‘their discoveries concerning the activation of 
innate immunity’; http://www.nobelprize.org/nobel_prizes/medicine/laureates/2011/press.html (accessed 
15 March 2016). Anthony (Tony) Cerami (b. 1940) is the founder and Chairman of the Board of Directors 
of Araim Pharmaceuticals; http://anthonycerami.org/site/ (accessed 15 March 2016).
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Michel Dayer, who was a bit like us in that he was looking at production of 
proteinases by connective tissue cells but in a slightly different way.54 They found 
that cachectin stimulated fibroblasts to make collagenase and prostaglandins. 
These experiments were all being done around the same time, and the upshot 
was really that TNF was an IL-1-like inflammatory hormone, but it was also 
cytotoxic to some tumour cells. A striking difference between them that was 
shown by Charles Dinarello and others in the paper in the Journal of Experimental 
Medicine in 1986, I think, where they showed TNF was a pyrogen, and that 
TNF could cause production of IL-1, but IL-1 didn’t cause the production 
of TNF.55 That’s how TNF became an inflammatory cytokine, and really the 
cell death side of it has always been a bit of a mystery to me because to make 
it cytotoxic you have to do tricks in tissue culture. The original Lloyd Old 
paper in the Proceedings of the National Academy of Sciences (PNAS) has the 
famous pictures of the black necrotic transplanted tumours, and I think it is 
possible that the TNF was causing thrombosis of the precarious blood supply of 
these tumours.56 It was possibly killing them by causing infarction. But I think 
the anti-cancer aspect never bore fruit, and what we had was an inflammatory 
mediator. Then people said, ‘Are these potent inflammatory hormones present 
at sites of inflammation?’, and I don’t know who was really first to show this 
in, for example, RA. The Edinburgh group of George Nuki and Gordon 
Duff measured IL-1 and TNF in synovial fluid,57 and Marc Feldmann and his 
colleagues were carrying out similar investigations.58
Balkwill:  I think that we could go in two directions now: back to the cancer or 
on with the rheumatoid story. I think we should carry on with the rheumatoid 
a bit longer, but there are a few things I’m sure others would like to come back 
on; for example, cell death, especially in those early days. 
54 Dayer, Beutler, and Cerami (1985). Jean-Michel Dayer is Emeritus Professor of Medicine at the 
University of Geneva; http://loop.frontiersin.org/people/295807/bio (accessed 22 March 2016).
55 Dinarello et al. (1986). For Professor Charles Dinarello, see note 48.
56 Carswell et al. (1975).
57 See, for example, Waalen et al. (1986), Di Giovine et al. (1987) and Di Giovine, Nuki, and Duff (1988). 
Professor George Nuki is Emeritus Professor of Rheumatology in the University of Edinburgh; http://
www.research.ed.ac.uk/portal/en/persons/george-nuki(287eed5a-9efc-47dd-9c6a-ebd2c377536b).html 
(accessed 22 March 2016). Professor Sir Gordon Duff is the Principal of St Hilda’s College (University of 
Oxford); http://www.sthildas.ox.ac.uk/college/college-non-academic-staff (accessed 22 March 2016).
58 Buchan et al. (1988).
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Feldmann:  I’d like to pick up on the very important bit of science, which was 
how did these potent supernatants end up as very defined, precise molecules? 
Instrumental in moving the field forward was Jo Oppenheim, who started to 
organize conferences on these mediators, from about 1978, first in Washington 
but then they became global, to try and get the people in the field together to 
discuss their findings.59 I was privileged enough to be a friend of his and to go to all 
of these. And it’s from these meetings, as they got bigger, that the nomenclature 
‘IL-1’, ‘interleukin-2 (IL-2)’, ‘cytokines’, ‘monokines’, ‘lymphokines’, became 
much more adopted. But I think it’s important to bring out that the molecular 
basis of this field was dominated by the biotech industry, which was in a very 
different form to what biotech is today, and companies like Immunex and 
Genentech and a few others cloned most of the inflammatory mediators.60 The 
first one cloned in 1979 was IFN beta (IFN-β) by Tada Taniguchi,61 but from 
then on it was essentially by the companies. As you know, for the definition of 
molecules in human disease tissue, the tools were really important. Without 
the appropriate tools, progress would not be made. So the cloning of cytokine 
genes, of the TNF family, was done at Genentech, of IL-1 was done in Immunex 
and, partly, by Charles Dinarello,62 and we could spend the afternoon discussing 
some of the entertaining behaviour that went on with their competition, but 
we won’t. [Laughter] And Hoffmann-LaRoche63 was also involved in IL-1, but I 
think they didn’t clone it as such; they did the biochemistry. 
Saklatvala:  They cloned the mouse one, which was actually a gene for IL-1α.
Feldmann:  I’m talking about human diseases. 
59 Dr Joost (Jo) J. Oppenheim is a Senior Investigator and the Head of the Cellular Immunology Section at 
the Center for Cancer Research of the National Cancer Institute at Frederick, MD, USA; https://ccr.cancer.
gov/Cancer-and-Inflammation-Program/joost-j-oppenheim?qt-staff_profile_tabs=3#qt-staff_profile_tabs 
(accessed 16 March 2015). For more details on the conferences, see Feldmann (2009). 
60 Immunex (founded in 1981, Seattle) is a biotechnology corporation acquired by Amgen in 2002. 
Details of Immunex Corporation Records, 1983–2002, are available on Archives West; http://archiveswest.
orbiscascade.org/ark:/80444/xv43105 (accessed 22 March 2016). For Genentech, see note 50. 
61 Taniguchi, Fujii-Kuriyama, and Muramatsu (1980). Professor Tadatsugu Taniguchi is Emeritus Professor 
at the University of Tokyo; http://www.iis.u-tokyo.ac.jp/~mol-immu/en/top/biography.html (accessed 22 
March 2016).
62 For Professor Charles Dinarello, see note 48.
63 Hoffmann-La Roche & Co (founded in 1896 ) is currently known as ‘Roche’. For more details on the 
company’s history, see: http://www.roche.com/about/history.htm (accessed 22 March 2016).
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Saklatvala:  Then Phil Auron and Charles Dinarello and colleagues cloned the 
human one, which was for IL-1β (IL1B), and Immunex were trying to clone 
both human forms.64 Steve Gillis at Immunex had the Dinarello paper to review 
and rejected it for Nature. However, they took the sequence, which they then 
used to file a patent on IL-1 when a financial milestone with a big pharmaceutical 
company – who was supporting them – was due. So it appeared that to save their 
company and their project, they took the IL1B sequence from Charles Dinarello 
and Phil Auron. The affair became the subject of a long legal battle.65 
Feldmann:  I think this is a red herring. 
Saklatvala:  Red herring, but it’s an interesting story. 
Balkwill:  Walter Fiers also cloned TNF, both mouse and human, didn’t he?66
Feldmann:  That was also from the biotech base. But really, the biotech industry 
provided the tools, the complementary DNA (cDNA) probes, the antibodies 
that could be made from the recombinant proteins, and recombinant proteins 
for looking at human disease tissue. The approach that Tiny and I, and our 
colleagues, took was to focus on what cytokines were produced locally, so we 
studied messenger RNA (mRNA) production using cDNA probes. Gordon Duff 
was interested also in local production; he used immunohistology.67 Other people 
looked at cell supernatants and synovial fluid. Every technique was used, and the 
results were concordant that in the most accessible inflammatory human disease 
site – rheumatoid synovial tissue – every cytokine possible was detected. This 
was the basic dilemma, that the initial thinking that knowing what cytokines 
were present would give you an understanding of pathology and pathogenesis, 
and, importantly, a potential therapeutic target. This did not happen, and it was 
actually a very interesting but challenging time to unravel which of many pro-
inflammatory and other cytokines might actually be therapeutic targets. 
Maini:  I think when Marc and I got together and were interested in defining 
the cells that were producing these cytokines, and what was regulating them, 
it became evident that macrophages were the producers of TNF and IL-1, but 
64 Philip E. Auron is a Professor and Chairman of the Department of Biological Sciences at the Duquesne 
University; http://www.duq.edu/academics/faculty/philip-auron (accessed 22 March 2016).
65 See, for example, Wolff et al. (1986). 
66 Marmenout et al. (1985).
67 For Professor Sir Gordon Duff, see note 57.
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interleukin-6 (IL-6) was produced by fibroblasts. We couldn’t show T cells 
producing anything by immunocytochemistry. They seemed to be there as 
silent cells, but in fact with Marc and Taniguchi, we did some experiments 
which did demonstrate some IFN-γ in the joint being expressed.68 We know 
today that basically these were tired T cells that had been over-stimulated and 
had gone into a kind of quiescent phase, which didn’t mean that they hadn’t 
played an important part, as they’d already done their bit. Basically, we now 
know that another kind of T cell, the ‘T helper 17’ (T
h
17) cell,69 and such other 
cells, are perhaps being the real rascals, whereas people then were only looking 
at IFN-producing T cells. 
I think that the situation was much more complex than we could see in a 
simplified way, because of the limits imposed by reagents available for study. 
It became evident that RA was not only an adaptive immune disease, but also 
an innate immune disease, and I think that was a very important conceptual 
advance. Then the question was, ‘How were they interrelated?’ Subsequent 
work has shown the interrelationships that exist and are orchestrated in chronic 
disease. It seems that at the beginning of the disease, a more predominantly 
active part is played by the T cells, and later on the innate immune response 
comes into being, and, of course, the antibody response is increasingly 
recognized as important as well. And, although all these immune responses have 
been demonstrated, the only test that can prove the pathogenic role for any 
particular molecule is by treatment interventions which block or enhance their 
activity. That’s the only way we could know that TNF blockade works for the 
treatment of RA, and that IL-6 blockade works well too, and T
h
17 blockade 
works, but not so well. Since we’re talking about RA now, we should mention 
that B cell depletion and blockade of co-stimulation of T cells are also effective. 
You can begin to see some kind of a sequence with HLA presentation of antigen 
by T cells setting off a complex response. Maybe the reason anti-T cell activity 
blocking works actually is because of the blockade, not only of T cell activity, 
but also of cytokine production downstream. The same thing could be true for 
the B cell, that the reason B cell depletion or blockade works is because immune 
complexes are important in perpetuating RA. 
Balkwill:  And also, B cells make loads of cytokines as well. 
Maini:  In their own right, yes. 
68 Buchan et al. (1988).
69 See, for example, Furst and Emery (2014).
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Kalden:  As Tiny was saying, I think it was exciting work; it was an exciting 
time. We all had defined new targets for immune intervention in RA patients; 
the only thing which was really left to us was to prove which one would be the 
right target by performing clinical trials. Just take the IFN-γ story, for example. 
In Germany at this time, IFN-γ was used for treating RA patients based on a 
small bit of evidence. In some of the patients being treated positive changes 
with regard to signs and symptoms were observed, but after quite a time this 
trial was stopped since no real differences were seen between patients treated 
with verum as compared to the placebo.70 As in the early days, there is still today 
a search for new targets for the intervention of the clinical outcome of RA. This 
is because not all patients will respond well to the biologics developed towards 
the end of the last century. 
Another cytokine, which has turned out to be a good target for immune 
intervention, is IL-6. Of interest is that a French group published, in the early 
1990s, data indicating that blocking IL-6 was treating RA effectively. Thus, 
discussing different targets indicates that there might be different pathways 
which dictate the clinical picture of RA. 
Balkwill:  Would you say then that you hit the jackpot, as it were, with TNF, but 
that it could have been another cytokine target – it could have been IL-6, or was 
the data stronger for TNF?
Feldmann:  I think there’s endless potential for speculating how history might 
have been different to what it was. I believe that I can represent the history as 
it actually took place, because a lot of what was successful took place in the 
laboratory that Tiny and I ran at the Charing Cross Sunley Research Centre, as 
it became part of the Kennedy Institute.71 I think if we wanted to do revisionist 
history, maybe that’s for a different afternoon. 
The key dilemma at the time was which of the numerous pro-inflammatory 
mediators that could be shown to be produced in the joint: IL-1, as Jerry 
pointed out; IL-6; TNFα; granulocyte-macrophage colony-stimulating factor 
(GM-CSF); IFN-γ: these were all known to be expressed in joints by about 1988 
– which, if any, of these was a therapeutic target? It was quite interesting that 
the emerging concept of cytokine redundancy, for some researchers, acted in a 
70 In a trial, the ‘verum’ is a drug containing an effective substance, as opposed to a ‘placebo’.
71 The Charing Cross Sunley Research Centre was acquired by the Kennedy Institute of Rheumatology in 
1992; http://www.kennedytrust.org/history.html (accessed 21 March 2016).
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rather negative way, because the production of recombinant cytokines allows 
unphysiological experiments to be done. You can put in this purified protein 
on cells or cell lines at unphysiological doses, and you can get a huge amount of 
biology that may never have happened in vivo, because you never get so much 
of the protein into tissues. So it became clear that for purified recombinant 
cytokines, the inflammatory mediators appeared to have very similar functions 
and that was the concept of ‘redundancy’ that TNF, IL-1, GM-CSF, overlapped 
in properties quite extensively when studied in vitro. Study in vivo was not 
very easy because if you put in a trigger, if you put in your purified signal in a 
mouse or a human, it doesn’t stay a purified signal, lots of activation happens. 
So the dilemma, really, was to find out what might be the best therapeutic 
target. Actually, we started in this field with the prejudice, common at this time, 
that IL-1 might be the right target based on Jerry’s point that if you put IL-1 
into cell cultures or the knee joint of a rabbit, you get more damage than if you 
put in other things. 
The key experiment was performed by our ex-colleague, Fionula Brennan, who 
regrettably isn’t with us anymore.72 She was a postdoc at the time, a very good 
postdoc in fact, and she first worked with Tiny, then came to work with me and 
she inherited from Glenn Buchan, a New Zealand postdoc who had driven our 
work on the molecular biological approach to identify mRNAs in the joint.73 
The dilemma was to try and sort out which of these, if any, was the best target. 
The technology at the time that led to the ‘breakthrough’, which I think is an 
appropriate term for what happened subsequently, was really to use cultures of 
rheumatoid synovium. This is an experiment that’s hugely challenging to do 
now because volunteers who give up their synovium have diminished greatly 
as patients are treated better. But, at the time, the synovium was available from 
a number of surgical procedures, and Tiny had organized a very good and 
effective network to collect this material. It arrived in the lab and the key step 
was to develop the culture system that mimicked the biology in the joint, and 
keep the cells alive and functioning for about 6–7 days so you could study 
the interactions, and the mediators produced. It turns out that my initial PhD 
project in Australia on optimizing immune cell cultures from the mouse spleen 
was very helpful. 
72 For Professor Fionula Brennan (1957–2012), see biography on page 83. 
73 Glenn Stuart Buchan (1956–2008) served as an Associate Professor in the Department of Microbiology 
and Immunology, University of Otago; see http://www.otago.ac.nz/propertyservices/commemorative-
register/otago074977.html (accessed 22 March 2016). 
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When I started the PhD project in 1969, mouse spleen cell cultures worked 
very occasionally. But it turned out that, with attention to many details, these 
cultures could be made to work. So I was revisiting things I had done before, and 
with Fionula Brennan doing the lab work and a little bit of suggestion from me, 
she developed a system whereby the cells in the joint stayed alive for essentially 
about 5–6 days, and kept producing the mediators that were believed to be 
produced in vivo. And so she was able to do the key experiment, which was to 
measure IL-1 from synovial cultures under different conditions. This was done 
by a very high-tech test known as ‘thymocyte proliferation assay’. There were 
no biochemical tests, or binding assays sensitive enough at the time to measure 
IL-1. As immunologists, we used the simplest experiment that Tiny already 
alluded to, blocking antibodies. By collecting antibodies from the biotechs 
that had cloned these cytokines, and made antibodies, we put antibodies into 
synovial cultures, and the breakthrough was made with a rabbit antibody to 
TNF that we got from Genentech. 
I think it’s worth putting on the record that the scientific social behaviour 
of biotech in the 1980s was quite different to what it is today. We obtained, 
from scientists I knew, a whole range of recombinant cytokines, very precious 
proteins, with no Material Transfer Agreements (MTAs), no paperwork, no 
nothing. They were just given to you for the furtherance of science and it’s 
possibly a sign of insipient senility, but one wishes that science worked like this 
today. Needless to say it certainly doesn’t. 
Mike Shepard, who was on the list to attend today, was the scientist at 
Genentech who was in charge of extramural collaborations, and he was very 
instrumental in giving us a whole lot of reagents, which ended up enabling us 
to show that the blockade of TNF in cultures was effective.74 Fionula Brennan 
showed that in seven consecutive rheumatoid cultures, anti-TNF switched off 
the production of IL-1 assayed by the thymocyte assay, within two days. Seven 
out of seven osteoarthritics didn’t change, and so that was really the pivotal 
experiment that showed that blocking one inflammatory mediator, TNF, also 
blocked another one that was as potent, IL-1, and that gave us a clue that there 
may be a pro-inflammatory cytokine cascade of TNF driving the production of 
74 Dr Michael Shepard worked in Genentech on the development of monoclonal antibody therapeutics 
from 1980 until 1992; http://warrenalpert.org/prize-recipients/michael-shepard (accessed 22 March 2016).
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other cytokines.75 That was the first clue, if you like, that TNF was the potential 
therapeutic target, a single mediator, that, if blocked, might have capacity to 
change clinical behaviour in patients. 
Balkwill:  Should we now talk about the commercial side of the story and the 
clinical exploitation, or should we go back to the cell killing and the cancer 
story of TNF now, rather than go further with the rheumatoid story?
Chernajovsky:  Historically, many of the people who worked on IFN started 
working on TNF. IFN was a cytokine that was discovered in the 1950s, 
and there was a very potent biological assay for it that was ‘viral replication 
inhibition’.76 For most of the cytokines that were cloned at that time, there 
were not very good assays. The way that people cloned and managed to get 
the IFN genes was by an incredibly difficult methodology; that was to inject 
phages into the nuclei of frog oocytes, and assess the supernatant of every 
oocyte by testing in an antiviral assay. So all the cytokines that came afterwards 
when they were cloned, they were cloned because certain biotech companies 
had certain assays that other people didn’t have. It was very difficult at the 
75 Brennan et al. (1989). For a simplified overview of the main biological actions of TNF in RA, see 
Appendix 2.
76 For more details, see Pestka (2007).
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time to be able to demonstrate that what you had was something new that 
had biological action. I also think that some of the reasons why people from 
the IFN field moved into TNF was because they had a lot of experience in 
trying to understand the mechanism of action of biological compounds that 
not everybody had at the time. 
Maini:  I just wanted to explain that the possibility that biological therapy would 
be of any benefit in RA was really received with great scepticism, as it would 
be for any chronic disease. When monoclonal antibodies were discovered in 
1975,77 because they were murine monoclonal antibodies, they were highly 
immunogenic and because of their immunogenicity the initial thinking was 
that they would only work – if they worked at all – for acute indications. Of 
course, mouse-derived anti-T cell antibodies were used in transplant rejection, 
successfully, for one of the first applications for an antibody therapy.78 Then 
we had the technology for developing chimeric antibodies, which were shown 
to be perhaps less immunogenic. But to produce these in quantities that were 
required for treating diseases that are chronic in nature was a formidable 
challenge. When we first thought of anti-TNF antibody use in RA, the major 
limitation was not only persuading someone who already had such a reagent 
to allow us to use it, but that they would be able to produce enough quantities 
for a valid clinical trial to be done. We underestimate, now that the engineering 
of antibodies has become such a normal phenomenon and kilograms of the 
material are produced reproducibly, that this was not the case in the 1980s 
when Marc and I were struggling to move from these pre-clinical experiments 
into the clinic. 
I should also mention that we had this really rather naive idea arising from 
Marc’s laboratory. He had a chap called Pat Gray working with him who had 
cloned a variant of a TNF receptor, which was highly effective in blocking TNF 
in vitro.79 We did, at one time, think that the Kennedy Institute would actually 
be able to produce enough for us to treat patients. Marc tried his contacts with 
industry to try and persuade them to make this therapeutic for us. And before 
we go to the next phase, which I’m sure we should hear about shortly, Jim 
77 Köhler and Milstein (1975).
78 See, for example, Prentice et al. (1982). 
79 Gray et al. (1990). Dr Patrick W. Gray is Chief Scientific Officer at BioMmune Technologies; see http://
www.biommune.net/board/ (accessed 22 March 2016).
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Woody appears on the scene from Centocor who already had such an antibody.80 
I think we should divert for a moment and recall that monoclonal anti-TNF 
antibodies for clinical use were actually developed for treating sepsis, and we 
haven’t mentioned sepsis until this moment. The work of Bruce Beutler and 
Anthony Cerami showed in a mouse model experiment that sepsis caused a 
cytokine storm, and this cytokine storm caused multiorgan failure, which you 
could prevent by giving anti-TNF antibodies at the onset of the induction of 
sepsis.81 So when we were doing the experiments with RA, there were only two 
scenarios in the clinic: one of TNF as a treatment for cancer and of anti-TNF 
as a treatment for sepsis. 
Feldmann:  I think it’s also worth remembering that the concerns about antibody 
therapy were really dominated by cost. So the belief was that the cost of these 
therapies would not be suitable for chronic use. In fact that probably still is 
the case, but it hasn’t stopped progress. The sepsis hypothesis that Tiny alluded 
to, had led to a number of companies making anti-TNF monoclonals, and 
they made this for the mirage of treating 300,000 Americans who were dying 
annually of sepsis, and that this could lead to a one-shot treatment to rescue 
them and make a lot of money. It resolved the really huge dilemma of new 
medicine: that when you discover a therapeutic target, can you actually get a 
therapy? This particular dilemma had been resolved. 
There were about half a dozen different antibodies. We could spend a lot of 
time talking about the ‘Why was it difficult to get British companies to work 
with us?’, but it’s inappropriate because it would also take hours. This is where 
Jim Woody came on the scene to really help us, so Jim should say more about 
it. Basically, he was the first person we could convince to take our hypothesis 
seriously, and he and the company he’d joined recently, Centocor, to work with 
us to move these very interesting laboratory findings into a Proof-of-Principle 
(PoP) situation and early clinical situation.82
80 Centocor was founded in 1979, and in 1999 became a wholly-owned subsidiary of Johnson & Johnson. 
In 2008, Centocor and Ortho Biotech Products merged to form ‘Centocor Ortho Biotech’, while in 2011 
the company acquired its current name: ‘Janssen Biotech’. For more details on the company’s history and 
activities, see https://www.janssenbiotech.com/company/history (accessed 16 March 2016).
81 Beutler, Milsark, and Cerami (1985). 
82 The PoP refers to an evaluation of the effect of a new drug/treatment on specific disease biomarkers, but 
not necessarily on the clinical endpoints of the disease. Professor Sir Marc Feldmann commented: ‘while 
PoP doesn’t need clinical endpoints, they are always looked for, and in our case were very obvious.’ Note on 
draft transcript, 24 May 2016.
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Jim Woody did a PhD at UCL under my tender loving care. He was meant to 
get Avrion Mitchison to supervise him, but Avrion didn’t want to and instead 
Jim got me.83 He completed his PhD in the minimum possible time, which is 
what the medics can do and the science students can’t do. The medics know that 
to survive they have to be organized and if they’re going to move to another job 
they’ve got to finish precisely on time. He was one of those people, so a really 
good student to have. He’d come as an American to do a PhD much quicker 
than possible in the US. Jim, do you want to come in and explain?
Dr James (Jim) Woody (via phone):  I believe the pivotal experiment from our 
point of view was done by Fionula Brennan in Marc’s lab.84 At the Kennedy 
Institute, Marc and Tiny had put together a very good programme, and they 
were able to culture human joint tissue and study the cytokine production 
for several days. That was a very informative set of experiments from our 
perspective, because any time you have human tissue as opposed to animal 
models, the human tissues are much more informative. Fionula was able to 
show that the blockade of TNF eliminated the downstream cascade of cytokines 
in these cultures, and that indicated to us that it would be worthwhile doing 
83 For Professor (Nicholas) Avrion Mitchison, see note 30.
84 See note 72.
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a clinical trial with an anti-TNF, which we had. Interestingly, we had already 
done a trial in 30 or 40 sepsis patients where we were disappointed, because the 
anti-TNF, unlike the predictions, didn’t do very much; certainly not the benefit 
we had hoped. So when Marc and I discussed the experiments Fionula had 
done plus all the background information you’ve heard about this morning, it 
became clear that a trial in patients with RA was warranted. So we arranged to 
go ahead and do that in about 1992.85 
Professor Henning Walczak:  From my understanding, and I joined the field 
quite a bit later; I realize you started in 1966, the year I was born. After finishing 
my undergraduate studies in 1990 I was led into it by another article in Scientific 
American that made me visit some labs at the German Cancer Research Centre 
where scientists work on these cytokines. Shortly thereafter I started working on 
cell death for my Master’s and PhD theses. Following my time in Heidelberg, I 
joined Immunex in Seattle and, of course, Immunex was mentioned before in 
a bit of its more shady aspect. Later on Immunex, of course, cloned one of the 
TNF receptors, namely ‘TNF receptor type 2’ (TNFR2) and had constructed 
an Fc protein that consisted of the extracellular portion of TNFR2 joined to 
the Fc portion of IgG1. This recombinant protein was able to block TNF. And, 
of course, Jim Woody – who is on the phone – and whom I also met when, 
together with Peter Krammer, my PhD supervisor at the time, I went to visit 
Centocor and talked about the possibility of working together with them on 
another TNF super family member and its blockade, namely ‘APO-1 ligand’, 
or ‘Fas ligand’ as it’s known more globally.86 
Coming back to TNF, for me the question is: how did the race unfold? At 
some point it had become clear that TNF blockade could potentially work as a 
therapy in RA and as far as I understood – at least from my time at Immunex, 
and I was there in 1996, and 1997, the time when Enbrel was being licensed – 
Enbrel was the first TNF blocker to be licensed as a treatment for RA.87 There 
was, of course, the antibody that Jim Woody and Centocor had been working 
85 Dr Jim Woody commented: ‘Ironically the company was unenthusiastic, but the science prevailed, and 
we were able to initiate the first clinical trial.’ Note on draft transcript, 13 May 2016.
86 The APO-1 (meaning ‘apoptosis antigen 1’) receptor is also known as ‘cluster of differentiation 95’ 
(CD95), and it is a cell surface receptor that can lead to programmed cell death (apoptosis) upon its 
activation by the APO-1 ligand. 
87 Etanercept (Enbrel®) was developed by scientists at the Immunex Corporation; Mohler et al. (1993). 
Immunex was acquired by Amgen in 2002. For an overview of the drug’s indications, see Appendix 3.
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on.88 There was indeed another antibody that was developed just across the 
Rhine from Heidelberg at Knoll, which was part of BASF, and which was later 
acquired by Abbott.89 
Kalden:  That was the first humanized anti-TNF antibody.
Walczak:  Yes, but my question is how did the race unfold once these different 
molecules had become available to go into the clinical trials?
88 Infliximab (Remicade®) was developed by Centocor (now ‘Janssen Biotech’). For an overview of the 
drug’s indications, see Appendix 3. Professor Sir Marc Feldmann commented: ‘it might be good to point 
out two other important contributors; Jan Vilcek at NYU whose lab made the original hybridoma that was 
genetically engineered by John Ghrayed at Centocor.’ Note on draft transcript, 24 May 2016.
89 Adalimumab (Humira®; trade name stands for 'human monoclonal antibody in rheumatoid arthritis') 
was collaboratively developed by BASF Bioresearch Corporation (Worcester, Massachusetts) and CAT as 
‘D2E7’, then further manufactured at BASF Bioresearch Corporation and developed by BASF Knoll (BASF 
Pharma) and, ultimately, manufactured and marketed by Abbott Laboratories after the acquisition of BASF 
Pharma by Abbott. In 2013, Abbott split into two companies, one retaining the Abbott name and the other 
named ‘AbbVie’ (the current owner of Humira®). For more information on the D2E7 development, see 
Kempeni (1999). For more details on the drug profile, see respective Drug Profile (authored by B. Yang) 
at the Discovery Medicine website: http://www.discoverymedicine.com/Benjamin-Yang/2009/05/21/drug-
profile-humira/ (accessed 15 March 2016). For an overview of the drug’s indications, see Appendix 3.
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Feldmann:  I think it’s important to establish the exact chronology of the PoP 
early clinical trials. This was done in 1992 with what became ‘infliximab’, which 
was known at the time as ‘cA2’.90 So this was an experiment that was done with 
Centocor, with Jim Woody, but not with the professional clinicians at Centocor 
because they were chasing CD4 T cells as the cure of RA, and they were not as 
impressed as Jim was about anti-TNF. So from May 1992 through to about July 
1992, Tiny treated ten patients, or probably only nine by then.
Since 1984 we have held scientific meetings to help translational research, and 
we had one of these in September 1992 – it was one of the few that was not 
at Trinity College (Oxford); this one was in Israel, on the Dead Sea in Arad.91 
We asked Centocor for permission for Tiny to present the results, and in their 
wisdom they agreed.92 My friends from Immunex, Genentech, Roche etc., were 
all present. Tiny disclosed that nine patients had responded really well to anti-
TNF therapy. That was an important event for the patients, because it went 
from being one company half-heartedly pursuing anti-TNF therapy to three 
or four companies pursuing the same goal with rather larger resources. I think 
that’s been terrifically good for patients. Do you want to amplify, Tiny?
Maini:  Yes. I think the scepticism I referred to earlier was quite a dominant, 
negative force when we wanted to go into man, into clinical trials. A lot 
of our academic colleagues didn’t believe this would work, and might be 
harmful. There was the question of immunogenicity, cost, and all these 
factors that were real obstructions, roadblocks to progress. It was the 
foresight of someone like Jim, who could see maybe an alternative use for a 
product that Centocor had developed for treating sepsis, that didn’t seem to 
be working in sepsis, that allowed us to do the key experiment. The results 
were so dramatic that, Jim, you may recall, some of your senior directors 
visited London and actually cross-examined me in great detail about how 
good this really was. We had to show them our lab books and our clinical 
data to prove the dramatic benefit that had ensued, including repeat biopsies 
in patients that we had performed. 
I think that the persuasion was sufficient then, not only to do a very complete, 
open label trial – open label because we were not at all sure how harmful this could 
be to our patients, so they had to be supervised with great care and caution – to 
90 See note 88.
91 For more details about this meeting, see Feldmann (2009).
92 For Centocor, see note 80.
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be quickly followed by a placebo control trial that conclusively showed a dose 
response to infliximab, called ‘cA2’ in those days, in RA patients.93 That was the 
first multicentre trial in which Joachim Kalden from Germany, Josef Smolen in 
Vienna, and Ferdinand Breedveld were co-opted by me, because they were my 
friends, to take part in this trial.94 They were all experienced in treating RA, so 
this seemed a very good group to get together. Basically what happened was that 
a British idea, with European help, was facilitated by an American company. 
And the PoP was dramatic in this trial as we published in The Lancet.95 We 
also published a follow-up study that demonstrated that the clinical response 
only lasted for the duration of the antibody in the blood, and that as soon as 
the antibody levels fell somewhere below 1 μg/ml, the disease came back.96 So 
we then did the obvious experiment, which was to repeat treatment with this 
antibody and showed the same level of response but in a significant number 
of patients. In a small number of the patients whom we treated, the duration 
of response diminished and we could show that this was very likely due to the 
development of antibodies, blocking antibodies, to the antibody that we were 
using for treatment. 
So that was the score in 1993/4 when, in the meantime, both Roche and 
Immunex became involved in the race to develop their therapeutic soluble TNF 
receptors for treating RA. The Roche type 1 soluble receptor fusion protein was 
very effective, but turned out to be immunogenic as well, and in this case the 
immunogenicity led to rapid clearance and shortened efficacy.97 
Actually, one other factor came to light during these trans-Atlantic trials: 
in Europe, they were showing efficacy but the same product in the USA by 
Genentech, I think, was apparently not effective. This was a quality-control 
issue, so Roche was not only troubled by the fact that not only did their receptor 
fusion protein appear to be immunogenic, but, actually, they were not able to 
show convincingly its reproducible production. 
93 Elliott et al. (1993, 1994a).
94 For Professor Josef Smolen, see biography on page 88. Professor Ferdinand Breedveld is Head of the 
Department of Internal Medicine and Rheumatology at Leiden University Medical Centre; see http://www.
articulumfellowship.com/centres/NL_breedveld.html (accessed 22 March 2016). 
95 Elliott et al. (1994a).
96 Elliott et al. (1994b) and Maini et al. (1998). 
97 Rau et al. (2003).
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Kalden:  Stability was missing. 
Maini:  Stability of the receptor fusion protein was the other factor. Nobody 
thought at that point that the Immunex fusion protein would work in RA, 
because it had low-affinity binding and actually was a dissociable complex. 
People thought that this would be readily displaced when given in vivo and 
that it would not work very well, and actually it didn’t work as well as the 
antibody but it was much less immunogenic. The claim was made that it 
was not at all immunogenic. We now know, of course, it is immunogenic 
but the antibodies are not a significant factor in blockading the therapeutic 
action. There was one British company, a biotech company, Celltech, that 
also produced an anti-TNF chimeric antibody that was of an IgG4 class that 
was in clinical trials soon after the infliximab, cA2 trials that we did, that 
confirmed efficacy.98 Now this was the dramatic thing about the anti-TNF 
trials. Every biologic that was used was effective and the results were strikingly 
similar: 60 to 70 per cent of patients were responding and about 30 to 40 per 
cent weren’t. As a result, we began to realize that not every rheumatoid patient 
responds, but the reproducibility of the phenomenon was a huge boost to the 
development of these antibodies. First in the clinic for RA was the Amgen 
product in 1998 because, and Jim may like to comment on this, Centocor 
just did not have enough money to do the big trials we needed to do in RA.99 
Instead, they focused on Crohn’s disease and they got a licence for Crohn’s 
before anybody else, because, in fact, the Amgen anti-TNF did not work in 
that disease. 
Kalden:  Could I just add, around the same time, in 1993/4, Joachim Kempeni, 
working at a little company in Germany called ‘Knoll’ that was owned by BASF, 
produced a human anti-TNF monoclonal antibody.100
Maini:  No, no, no, it was produced by Cambridge Antibody Technology (CAT), 
by Greg Winter.101 
98 Rankin et al. (1995).
99 Etanercept (Enbrel®) was approved for use in RA in 1998; see Appendix 3.
100 See note 89.
101 Cambridge Antibody Technology (informally known as ‘CAT’; founded 1989) was a biotechnology 
company that focused on antibody therapeutics and that was acquired by AstraZeneca in 2006. Sir Gregory 
Winter was one of the founders of CAT and is currently the Master of Trinity College, Cambridge; http://
www.trin.cam.ac.uk/node/353 (accessed 22 March 2016). 
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Kalden:  Whoever produced this antibody, the small company Knoll was sold 
by BASF to Abbott. 
Feldmann:  The protein was made by CAT. That’s what the lawyers think and 
that’s what hundreds of millions of royalties paid by Abbott to the Medical 
Research Council (MRC) says. BASF commissioned the antibody from CAT, 
but BASF was bought by Abbott. 
Kalden:  No, no, BASF is still alive. It’s a big company. Knoll was basically part 
of BASF and then they sold Knoll to Abbott. 
Feldmann:  That is right.102 
Maini:  Knoll developed the CAT antibody clinical trials.103 
Walczak:  If I’m not mistaken, on the basis of the fact that scientists at Knoll 
had purified human TNF receptors, and I’m not sure whether it’s true but I 
heard it was actually purified from urine. Does anyone know whether that’s 
true or not? 
Balkwill:  Wasn’t it that the Italians used to collect urine from nuns to purify 
hormones, and Alberto Mantovani would tell you that they used this urine to 
purify the TNF receptors.104 
Feldmann:  The TNF receptor purification that led to patents was done in Israel. 
Balkwill:  By David Wallach.105 
102 Professor Henning Walczak commented: ‘in the meantime I have found out that indeed CAT acted as 
CRO (Contract Research Organisation) for BASF/Knoll in the generation of a humanised antibody against 
TNF and, as a function thereof, receives royalties on sales which, even though they were kept at a rather low 
percentage rate at the time, amount to massive sums because of the high sales of Humira […] it [Humira] 
was developed by BASF/Knoll with the help of CAT who acted as a CRO […] so far I have not been able to 
receive any official statement from BASF/Knoll or anyone involved on their side at the time, but I think the 
clarification I provide above should suffice to make the point within our document.’ E-mail to Dr Apostolos 
Zarros, 8 June 2016.
103 For more details, see Lorenz (2002).
104 Professor Alberto Mantovani is Scientific Director of the Humanitas Clinical and Research Center and 
Professor of Pathology at the Humanitas University, Italy; http://www.humanitas-research.org/mantovani-
alberto/ (accessed 22 March 2016).
105 David Wallach is Professor at the Department of Biomolecular Sciences at the Weizmann Institute of 
Science; see http://www.weizmann.ac.il/Biomolecular_Sciences/Wallach/ (accessed 22 March 2016).
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Feldmann:  David Wallach and the Weizmann Institute of Science group; we 
have to assume that the royalties they get on the patents mean that that is the 
correct history.106 
Walczak:  Yes, but I know that there are employees at Knoll, who are now 
at BASF, of course, who get royalties for having contributed as inventors to 
the development of the anti-TNF antibody now known as ‘adalimumab’ or 
‘Humira’, so there must be some connection with respect to what they have 
done on this as well. 
Woody:  Just to comment on some of the history: interestingly, Centocor was 
the first one to ever inject an anti-TNF antibody into humans. As Tiny pointed 
out, there was a lot of scepticism that this might be extremely toxic, and so we 
did a lot of primate studies to be sure that it wasn’t harmful, and it wasn’t.107 And 
in the sepsis patients that we treated, while they didn’t get better, they didn’t get 
worse either. So we had fundamental data for the first time that would allow 
us to go into rheumatoid patients. At the time there might be another product 
from Roche/Genentech, lenercept,108 that was a very potent anti-TNF inhibitor, 
but the fusion protein had a construct in it that turned out to be extremely 
immunogenic. So they had a hard time with that molecule for a long time. 
As Tiny pointed out, we were also conducting an anti-CD4 trial in patients with 
RA and also multiple sclerosis (MS), which eliminated T cells, but it failed, even 
though at the time it was thought that T cells were driving the disease.109 There 
are lots of reasons why people thought we eliminated regulatory T cells; not 
quite sure what the answer was to why the anti-CD4 trial failed. But all of this 
was going on; it was a very productive time for sure. We enjoyed the connection 
with Marc and Tiny, and also Joachim Kalden, Professor Josef Smolen, and 
106 Engelmann et al. (1989). Note that in this original article of the Weizmann Institute of Science (where 
David Wallach is the senior author), the assistance of the Cesare Serono Research Institute (Rome, Italy) for 
‘preparing the crude urinary proteins’ is acknowledged.
107 Dr Jim Woody commented: ‘the primate studies would have been confidential Centocor information 
submitted to the FDA with the cA2 Investigational New Drug (IND) submission. As I recall there was no 
significant toxicity identified with cA2 administration to the primates, which allowed Centocor to move 
forward with the initial clinical trials in patients with sepsis.’ E-mail to Dr Apostolos Zarros, 12 May 2016.
108 Lenercept is a fusion protein of the type I TNF receptor (p55) and a human Fc IgG.
109 The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI 
Analysis Group (1999) and van Oosten et al. (1997).
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Professor Ferry Breedveld.110 Interestingly, they put a few patients with psoriatic 
arthritis on this trial and their psoriasis went away, so we knew that the antibody 
would work in psoriasis. And Sander van Deventer in Amsterdam treated a 
Crohn’s patient with cA2, and that person got well, so Centocor actually got 
the drug approved for treating patients with Crohn’s who had fistular disease, 
which was the most rapid track for approval. It was only later, after Enbrel was 
approved, that Centocor got approval for RA and psoriasis, so there was a bit of 
history there that is interesting.111 
Feldmann:  One of the things that’s really important is to try and connect the 
history of the concepts as they move from the lab to the clinic. So one clinical 
trial that’s underappreciated was the follow up of the open-label study. The 
open-label study grew to 20 patients, seven of whom got retreated a number 
of times. The importance of a retreatment study, which Tiny has already 
mentioned, was that some of the patients were retreated multiple times, four 
or more times, and they had multiple responses. What this demonstrated 
conceptually was that on repeated blockade of TNF, as the patients got 
better again, they were still running exactly the same mechanism. This TNF-
dependent effect on other cytokines that could be demonstrated in humans 
from the clinical trials – for example, anti-TNF treatment of patients reduces 
serum IL-6 within a few hours112 – this was a formal proof that this TNF-
dependent cytokine cascade, first found in Fionula Brennan’s cultures, extends 
in vivo to patients. The retreatment success over a year, but reduced duration 
due to immunogenicity, validates the idea that this TNF-dependent cytokine 
cascade was operative and relatively stable with time. This is unlike cancer, 
where pathways are much more likely to change quite quickly. Of course, this 
is an underpinning of the use of antibody therapies chronically, because if 
the pathways are relatively stable you can predict that the sales or the use of 
monoclonal antibodies in cancer is for a much much shorter period than in 
chronic inflammatory diseases like RA. 
Maini:  I think one of the important underpinnings of the clinical trial’s finding 
was the mechanistic studies we undertook at the same time.113 That was unusual 
in a clinical trial. I don’t think there had been any clinical trial that I’m aware of 
110 For Professors Josef Smolen and Ferdinand Breedveld, see note 94.
111 See Appendix 3. 
112 Charles et al. (1999).
113 Maini et al. (1995).
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in which serial biopsies were done on patients’ joints, and serial samples from 
the blood were studied, as we did, to demonstrate a dramatic reduction in IL-6 
within hours, as Marc has alluded to, but also, within days, a change in the 
morphology of the joint’s pathology. When we repeated the biopsy of joints, 
we found difficulty because, instead of being a large, boggy joint with a lot of 
tissue, the joint had shrunk, there was very little fluid left in it. When you took 
the biopsy there was a dramatic difference; it was no longer so cellular. So it was 
quite obvious to us, very early on, by 1993/94, that a major effect of anti-TNF 
was on cell trafficking. 
Balkwill:  I can remember, because I was very inspired by your work when 
thinking about anti-cytokine therapy in cancer, especially by the fact that you 
were doing these clinical experiments on patient samples during a trial. But the 
one paper that I remember was where you actually took leukocytes from the 
patients and you radiolabelled them and then studied their trafficking, or not, 
into the joint in the presence of anti-TNF.114 I will never forget that experiment. 
I’ve always been interested in translational experiments, doing experiments in 
patients, and to see you doing something like that was really inspirational. 
Maini:  Just to clarify that: in fact, when we found this lack of cellularity, the 
hypothesis was that either the cells were dying or there was an effect on the 
trafficking of the cells into the joint. And to investigate it, what was done in 
collaboration with people at the Hammersmith Hospital, who were good at 
imaging joints with labelled cells, was to label polymorphs with indium-111, 
reinject these into RA patients, and you could do a γ-camera imaging of the knee 
joints and the hands, and we could show a dramatic difference in the retention 
of the radiolabel before and after treatment.115 It was these kinds of experiments 
that were really underpinning that this was going to be a very effective attack on 
the pathogenesis of RA. 
Balkwill:  But weren’t they also pioneering in general, because people in any sort 
of clinical trial, in cats or anything else, I don’t think at that stage that people 
really did try doing repeat biopsy? We struggle enough now. 
Maini:  I think that is correct. 
Balkwill:  But to me they were quite pioneering. And you also showed a reduction 
in matrix metalloproteinases (MMPs) as well, didn’t you?
114 Taylor et al. (2000).
115 Taylor et al. (2000).
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Maini:  MMPs and other cytokines. 
Balkwill:  When we, much later on, managed to persuade Centocor to do some 
studies in cancer patients with anti-TNF, the three things that really I thought 
of from the rheumatoid studies that you did were that: (i) the anti-TNF reduced 
other pro-tumour cytokines like IL-6; (ii) it reduced leukocyte trafficking into 
joints – as you know leukocytes trafficking in tumours is also a problem; and 
(iii) it also reduced MMPs and chemokines, which were involved. 
Williams:  Both Marc and Tiny have alluded to the second clinical trial in 
which patients were retreated with anti-TNF when the disease flared, and 
it was observed that patients developed antibodies to the chimeric antibody 
cA2 and it was hypothesized, as Marc said, that this limited the duration 
of the therapeutic effect. By then I was involved in pre-clinical studies in 
mice, and I had looked at the effect of TNF blockade in an animal model 
and it was found to ameliorate collagen-induced arthritis, but, as in patients, 
the duration of effect was limited, because the disease flared as soon as the 
antibody was cleared. And also, using hamster antibody, the mice developed 
antibodies to the injected hamster anti-TNF antibody. To try and kill two 
birds with one stone, we looked at the effect of combination therapy, using 
anti-TNF with anti-CD4, and it should be remembered that anti-CD4 was 
being tested around this time in a number of clinical trials. It was felt that by 
targeting the T cell response as well as the pro-inflammatory TNF mediated 
response, you could get a more sustained therapeutic effect. There was the 
additional benefit of actually preventing the antiglobulin response to the 
foreign antibodies that were injected. That really formed the basis, at least in 
part – I’m sure Marc and Tiny will comment on this later – of the rationale 
for the combination of anti-TNF with methotrexate; methotrexate being a 
drug that was in common use and that had an effect on T cell proliferation, 
and therefore was considered perhaps to be an alternative to anti-CD4 but 
with the same concept of targeting the immune response as well as the pro-
inflammatory response mediated by TNF. 
Kalden:  Tiny, I remember that weekend very well. We were in your home and 
we discussed the combination therapy. The discussion was centred on the issue: 
should we really combine the monoclonal antibodies with methotrexate? After 
a long discussion, we all agreed to combine a rather low dose of methotrexate, 
but it really took us the whole weekend until we decided to go ahead to see 
if this combination would be better than a monotherapy with either of the 
The Recent History of Tumour Necrosis Factor (TNF)
42
drugs alone.116 In addition, the charm of this study was that we decided to do 
some parallel scientific experiments with regard to the mode of action of the 
monoclonal antibody, looking at the blockade of different pro-inflammatory 
cytokines in the periphery, at acute phase proteins, and at the cell infiltration 
of the synovium. Thus, at the end of these experiments we had quite a good 
knowledge of how and where a blockade of TNFα would be efficacious in RA 
patients.
Balkwill:  I guess we’re around 1994 now. Marc, Tiny?
Feldmann:  So I think the dilemma in 1994 was how this would enter 
rheumatological practice. The trials till then had been quite short-term, and 
short-term trials in a lifelong disease don’t have much impact. So Richard 
already introduced the idea that in mouse models combination therapy could 
be used, and this could be an improvement on anti-TNF alone. What Richard 
[Williams] did first was a blockade of CD4 T cells on top of anti-TNF.117 That 
became a precursor to the most effective trials, which were combining low-dose 
methotrexate with anti-TNF. I think Tiny is probably best placed to discuss that. 
Maini:  It’s important for us to put in perspective both the positive and the 
disheartening side of the story in 1994. At that time, the results of the Immunex 
product that you heard about actually weren’t known because they hadn’t done 
any trials. The only anti-TNF agent that had been used in patients to date 
116 Maini et al. (1998).
117 Williams et al. (1994).
Figure 11: Professor Sir Ravinder Nath (Tiny) Maini (left) and Professor Henning Walczak (right)
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was the Centocor anti-TNF in RA with a placebo-controlled trial,118 and the 
repeat therapy trial,119 which showed that immunogenicity was going to be a 
limitation. So the question was whether we could devise a way of overcoming 
the immunogenicity for prolonged therapy, and initially we thought the best 
way would be to block T cells. But because Centocor had developed a CD4 
antibody as well as the anti-TNF antibody that we were using, and the anti-
CD4 had been in clinical trials in RA patients, it seemed obvious to Marc and 
me that we should use that combination in RA patients. But Centocor was very 
reluctant to do a combination trial. I think the reason for this, and maybe Jim can 
explain, was essentially to do with the fact that you couldn’t use two unlicensed 
products simultaneously, so that path was closed. The only well known anti-T 
cell drug that was in use at that time was cyclosporine, and that had been used 
in transplantation very effectively for preventing rejection. Indeed, there had 
been some early trials in RA showing that it had limited efficacy, so one of the 
things that Richard Williams did was to test the combination of anti-TNF with 
cyclosporine and he showed – I think this followed the work with anti-CD4 – 
that that also was effective.120 
We looked around for the possibility of using that combination, and engaged 
in correspondence with Jim and Centocor about a trial using that particular 
combination.121 But it soon became apparent to me, as a clinician, that there 
just weren’t enough patients on cyclosporine and that it was too toxic a drug 
to expose patients to in a blinded trial, when you hadn’t any hope of keeping 
patients on the active principle cyclosporine truly blinded, as they developed 
hypertension and renal problems, and so, it would be very obvious to the clinical 
trialists which patient was receiving what. The problem was that the effect of 
anti-TNF was so profound that the concern was how would we demonstrate 
an additive effect, and how would we design a trial that actually showed this 
synergy or additional benefit? Well, having considered the obvious cyclosporine, 
we then had to scratch our heads and wonder what else we could use. I think in 
1993 or 1994, Marc and I were writing to Centocor about long-term strategy 
and we proposed methotrexate mainly because it was commonly used, and 
we knew that it had a profound effect on innate immunity. All the work that 
118 Elliott et al. (1994a).
119 Elliott et al. (1994b).
120 Williams et al. (1998).
121 For Centocor, see note 80.
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was published to date on humans with methotrexate was that it was a strong 
inhibitor of polymorph function and of prostaglandins, and I think the feeling 
was that maybe here lay something that might be an adjunctive. 
There had been, at that time, no published work on methotrexate and adaptive 
immunity in man, to my knowledge. After we had designed the combination 
with methotrexate, because that seemed the most practical thing to do, it 
became clear to us and confirmed by a publication that arose, I think from 
France, that actually it did inhibit proliferation of T cells in humans.122 This was 
quite encouraging, but by then we had already embarked on this combination 
trial and, as Joachim Kalden reminded you, the exact construction of the trial 
required a lot of thinking. One of the principal concerns was that we didn’t 
do any more harm to these patients on anti-TNF. By then, we knew it was an 
immunosuppressive drug and especially caused the unmasking of tuberculosis, 
and we had also seen one patient with a lymphoma, so there was concern that 
this combination could prove to be more toxic. And the issue was, if we were 
going to use methotrexate, what dose should we use? We decided, after a long, 
long discussion that we had to go with the lowest possible dose. Now, let me 
remind you that methotrexate works from the accumulation of polyglutamates 
of methotrexate in the cell, and that blocks a number of pathways. The hope was 
that patients who were already on methotrexate and were showing continuing 
disease activity would have enough saturation of polyglutamate in their cells for 
any synergistic effect that we might be looking for; that’s how it turned out to 
be with the trial. 
In 1994 we began a multicentre trial, and it was completed by the end of 1995. 
We had the first data in our hands in 1996. When Jim Woody, Marc, and I saw 
this data, we were really astonished. What it showed was that anti-TNF on its 
own in three doses worked, and, interestingly, at the highest dose of anti-TNF, 
which was 10 mg/kg given repeatedly, immunogenicity was suppressed. There 
was hardly any immunogenicity at that dose. We were reminded, when we saw 
that data, of experiments that had been done in the 1960s by Av Mitchison 
and others on inducing tolerance to soluble immunoglobulin;123 that we were 
basically reproducing in man a similar kind of tolerogenic effect. But we know 
from their basic studies in mice, that this is short-term B cell tolerance, and 
it’s very quickly reversed. So the option from this data was either the highest 
122 Genestier et al. (1998). 
123 Mitchison (1964).
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dose of infliximab that would work long-term, or that the combination might 
work. The lowest dose of anti-TNF that was used was 1 mg/kg, and, at that 
dose, with 7.5 mg of methotrexate weekly, we saw a profound beneficial effect. 
Indeed, we also saw a reduction from 50 per cent immunogenicity to about 3 
per cent immunogenicity. For the first time it was apparent, I think, that low-
dose methotrexate, a minute dose, was actually a primary immune response 
suppressive agent. That was very encouraging, and that was only one of the 
reasons that that combination was working, because quite clearly it was also 
working in patients in whom no immunogenicity had been induced, and the 
combination was showing a very profound effect. 
To this day, I don’t think we really understand why a combination of methotrexate 
and every anti-TNF agent that has been tested, subsequently, shows an 
enhanced benefit. So, to cut a long story short, Centocor-based antibody trials 
with methotrexate were the first, and it was the first combination to be licensed, 
although Immunex got the licence for monotherapy first;124 they accelerated 
the work into clinic without having done any of the pre-clinical work, without 
having done any mechanistic studies. They just did clinical trials at high speed 
and at high volume in the USA, to prove that they had a very good therapeutic. 
They were in the clinic a year before Centocor, who meanwhile was trailing 
behind because they didn’t have enough money for RA trials of the size and 
design we wanted them to do. We said that, really, it’s no good just showing an 
anti-inflammatory effect, you also have to show a disease-modifying effect, and 
disease modification, as laid down by the Food and Drug Administration (FDA) 
and the regulatory authorities, required a two-year trial. And the read-out was 
X-rays of the joints which show damage changes. That was the reason that this 
trial that we then performed for the Phase 3 development with Centocor took 
two years, and the licence had to wait, I think, until 1999 because of this delay. 
So just to step back: the first combination therapy, the results of which we 
already saw at the end of 1995, early 1996, was when we realized that this 
could be a patentable finding. Publication was partly held up for that reason, 
but partly because, when we submitted this trial for publication, initially to 
The New England Journal of Medicine (NEJM), and then to The Lancet, it was 
turned down. Eventually, we had to go to Arthritis & Rheumatism, which is 
the most significant rheumatology journal, and we had three revisions before 
they accepted this trial because they kept on asking questions, being rather 
124 See Appendix 3.
The Recent History of Tumour Necrosis Factor (TNF)
46
disbelieving about the statistics or the findings.125 We had to go through several 
iterations before we could really nail it down that this truly was a very genuine, 
and very good, finding. When that trial was published, all other companies 
went for the combination therapy and very soon we had the Immunex (later 
Amgen) product etanercept with combination, and then adalimumab,126 which 
is the Abbott fully human antibody, which, of course, being less immunogenic 
followed. This drug in combination with methotrexate did not rely on 
suppression of immunogenicity, although that is a factor, and there are many 
people who have been studying the effect of immunogenicity of so-called ‘fully 
human antibodies’. They are immunogenic and there is no doubt that patients 
who develop antibodies have a significant reduction in their response. In a 
nutshell, I think we can conclude that, from 1994 to 1998, it was possible 
for us to show that combination of an anti-TNF monoclonal antibody with 
methotrexate, when used sequentially in patients with uncontrolled disease, was 
a very sensible way of treating RA, because methotrexate is a very effective drug 
as monotherapy. When methotrexate is given as monotherapy, 50 per cent of 
patients will respond very well, especially if it’s introduced early in the disease, 
and such patients don’t need any other drug; they are restored to a very good 
quality of life and can tolerate the drug very well. It’s the patient who isn’t 
in that good category that is an ideal patient for treating with combination 
therapy with anti-TNF. Our trial design actually demonstrated that because we 
treated these patients on methotrexate without interrupting treatment, in other 
words with no washout period, the combination ensured that there was enough 
bioactivity of the polyglutamates in these patients to show the combination 
actually was due to a methotrexate effect. 
Balkwill:  So is that the same basis for treatment now? What’s changed since 
then, or is it still very much accepted?
Maini:  Nothing has changed. The only thing is that the combination is now 
being used in the USA from the initial stages of the disease. So if you have 
very serious disease, rheumatologists will say ‘This patient needs combination 
therapy from the start.’ There is a school of thought that combination therapy 
might be better for RA and there are some trials which purport to show that; 
however, our friend Josef Smolen, who isn’t here today, has written some very 
125 Maini et al. (1998). 
126 See note 89.
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excellent papers that suggest this is unnecessary.127 The European League Against 
Rheumatism (EULAR) has published recommendations on how to treat RA 
and they have analysed the information in the clinical trial domain.128 The 
conclusion is that actually methotrexate alone, if used initially in combination 
with corticosteroids, is just as effective as methotrexate plus anti-TNF. 
Woody:  I can add some clarity to Tiny’s comments. At the time, to use two 
experimental drugs was very difficult just because of the regulatory hurdles that 
you’d have to get over. I think, unlike a lot of others, we were very open in terms 
of discussing the toxicity associated with anti-TNF and made it available to 
everyone in the field at meetings and otherwise, and we knew that there was a 
risk for infectious diseases. There was a concern about lymphomas too because 
we had had a case.129 We didn’t want the drug to go on clinical hold because 
it was providing benefits. So things like cyclosporine would have been one of 
the agents, along with anti-TNF, that would put people, we thought, at higher 
risk. So the use of small doses of methotrexate seemed a reasonable way to go 
and that was a major achievement that Tiny and Marc produced in terms of 
reducing the human anti-chimeric antibodies and allowing repeated doses of 
the drug, which is actually the same exact formulation that’s given today. So 
congratulations to them on a major, major achievement, including the damage 
of the joints being reversed. 
Feldmann:  I just want to add two things to what Tiny’s said. I think some of the 
difficulties in publishing the paper was from the nature of the trial.130 There were 
seven arms with about 15 patients per arm, and the statisticians that NEJM/
The Lancet use have quite different paradigms for what is a proper clinical 
trial. So, for example, in cardiovascular disease they’ve insisted on thousands 
per arm so we were some way away from optimal numbers. It’s not that we 
127 See, for example, Smolen, Aletaha, and Keystone (2005). Professor Josef Smolen was unable to attend the 
Witness Seminar. See also note 94.
128 Smolen et al. (2014). 
129 Dr Jim Woody commented: ‘Tiny will recall the first disclosure of this issue. It was complex, as the 
patient had been treated with many potent cytotoxic drugs for RA over the years, and had a previous lymph 
node biopsy for possible lymphoproliferative disease, read out as negative. It caused us to survey the RA 
data for the incidence of lymphoma in RA patients, which was much higher than the general population. 
So while we were cautious, and disclosed the issue, at the time it was unclear whether there was a correlation 
or not. As data became available, there was an obvious lymphoma risk to be weighed against the joint 
destruction benefit.’ E-mail to Dr Apostolos Zarros, 12 May 2016.
130 See note 125. 
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wanted to do 15 per group, but that was the best compromise because there 
were three different doses of anti-TNF, with or without methotrexate, so that 
adds up to seven arms. I think that was a major drive of the publication’s bias; 
the statisticians were probably trying really hard to show that the P values were 
probably statistical artefacts. I’m partially joking, but I think it’s challenging to 
try and publish things in clinical journals when you don’t obey the standard 
criteria or rules for what they would like to receive. But with methotrexate, I 
think the combination therapy use reveals a very important paradigm, which is, 
that for biologics to sell well, they’ve got to fulfil an obvious unmet need. At the 
time, the obvious unmet need was ‘what do you do with patients that no longer 
respond well enough to methotrexate?’ So, in this particular situation they can 
go straight onto an anti-TNF, and I think that’s been beneficial, since, as well 
as its efficacy, the simplicity of what you’re meant to do helped considerably 
to drive the sales and acceptance, because you weren’t asking the challenging 
thing of patients and physicians to stop existing therapy, you were just adding 
on to existing therapy. From the historical point of view, it’s worth emphasizing 
that anti-TNFs were the first antibodies to be used for chronic diseases and the 
first antibodies that sold in very large volumes. The sales are now pushing 30 
billion dollars a year. Currently, it is the most profitable drug class; it probably 
will get overtaken by Gilead’s treatment for hepatitis C if they get their own 
way on pricing, but that’s not going as well as they would like.131 Anti-TNF 
sales have had a major impact on the pharmaceutical industry. When we started 
with this project, big Pharma was mostly totally uninterested in antibodies as 
therapeutics. The attitude to our work with TNF blockade was, ‘this is going to 
be wonderful PoP, we’ll find some small molecules that will do the job better, 
and cheaper.’ And that, of course, hasn’t happened. So really, what we’ve had 
first with anti-TNF, but then with other antibodies, is a change in the way the 
pharmaceutical industry works. 
All big Pharma now sell and work with antibodies. Any of you who have type 1 
diabetes will know that repeated insulin injections is what you get and it works 
fine, and patients don’t complain. They’re not clamouring for pills because the 
insulin keeps them well and alive. So now, that paradigm, well understood by 
diabetics, but not previously understood by the chemically based pharmaceutical 
industry, has changed considerably and that’s a very major step forward because 
131 Gilead Sciences (founded in 1987) is a biopharmaceutical company focused primarily on antiviral drugs; 
http://www.gilead.com/about/corporate-history-timeline (accessed 22 March 2016).
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it’s enhanced the repertoire of potential therapeutics. It’s much easier now for 
small companies to develop biological therapeutics, as the risk of failure is lower 
than the much more challenging production of small molecule therapeutics. 
Walczak:  In terms of lessons learnt, it’s totally clear to me that at the beginning of 
the journey for anti-TNF antibodies, like you said, Tiny, it seemed unachievable 
clinically to get the required amount of antibodies produced. You were able to 
show that the concept works and subsequently the pharmaceutical and biotech 
industry, or the biotech industry, like Jim Woody and others, have shown that 
they can then deliver the antibodies if it’s required in the end; it can be done. 
I think the lesson to be learned from that for us as basic scientists interested 
in finding new ways to treat diseases is: don’t let yourself be talked down by 
people telling you, ‘Oh, we cannot make this into a drug.’ For example, right 
now there are, as you know, a number of therapies – apart from the cancer 
immunotherapies that are antibodies that work very nicely – which are based 
on antibody therapies that have worked in the TNF field. Now we can develop 
antibodies, and the pharmaceutical industry has accepted a number of cellular 
therapies like chimeric antigen receptor (CAR)-expressing T cells or T cell 
receptor (TCR) transgenic T cells; these therapies work extremely well in 
certain cancer entities yet the pharmaceutical industry, at least a major part of 
it, is still saying: ‘That’s going to be very difficult to translate, this is probably for 
academics to do it in certain centres, but we will never be able to translate that 
into major drug-like therapies’. I think you have shown that this statement is 
probably wrong, that we can take anything that works – if it works well enough 
Figure 12: Associate Professor Richard Williams (left) and Professor Sir Marc Feldmann (right)
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– into patients and that it can then also be produced effectively in a process that 
is acceptable to the FDA and European Medicines Agency (EMA), as it has 
been with antibodies. I’m pretty sure, I’m actually certain, that it will be possible 
to achieve that also with CAR- and TCR-transgenic T cell therapies. And that, 
for me, right now is the major lesson that I have already learnt today. 
Balkwill:  Just coming back to RA, I think, one stimulus for this explosion of new 
biologics is also that, in spite of this tremendous progress introducing the anti-
TNF in the therapeutic repertoire for RA patients, only two-thirds of patients 
do respond and some of those patients only partially. So there was the need, and 
there is still the need, to develop more biologics and discover new targets, and 
more vehicles to target these new targets. In addition, of course, they saw that 
as something which brings money if it’s successful. We have now more than 300 
molecules being tested in trials for immune intervention. 
Williams:  I just wanted to mention one other point, that clearly anti-TNF 
therapy has been extremely effective, but most cytokines are highly pleiotropic, 
and back in the 1980s there was a literature, mainly by Hugh McDevitt and 
Chaim Jacob in the States, showing in fact that administration of TNF was 
actually beneficial in animal models of, I think it was SLE and type 1 diabetes.132 
There was also at least one clinical trial in MS where anti-TNF therapy actually 
exacerbated the disease.133 So I don’t think this story is completely finished and, 
in fact, part of our current work is really addressing this question: what are the 
different roles played by TNF and in particular on the immune system? In fact, 
TNF is immunosuppressive and we’re currently investigating the molecular 
mechanisms involved, so I don’t think this story’s finished. 
Balkwill:  I think that’s a very good point, and something that maybe allows us 
to just divert off for a minute and think about cell death, cancer, and things like 
that. 
If I could just step back in history a bit, because not only was TNF given to 
mice as a therapy for autoimmune disease but, as we all know, TNF was given 
to treat animal cancers.134 And if you go back to Coley, probably Coley’s toxins 
did not induce just TNF, they might well have induced TNF amongst other 
132 See, for example, Jacob and McDevitt (1988). 
133 The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI 
Analysis Group (1999).
134 For more details, see Balkwill (2009). 
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things, but probably some beneficial T helper 1 (T
h
1) response, which we would 
understand a lot more now in our new knowledge of cancer therapy.135 But if we 
go back to when the first TNF was purified by Carswell and Old in 1975, and 
it was a Cancer Research paper, wasn’t it?
Saklatvala:  That was a PNAS paper, the one with the spectacular photographs of 
the assay showing the haemorrhagic necrosis; that was 1975.136 
Balkwill:  No, this was the purified protein, it wasn’t the cloned molecule, but for 
at least 10 years it was thought that TNF was toxic to malignant cells and not 
normal cells. Certainly, when we got hold of recombinant TNF from Walter 
Fiers in 1984/85, it was very clear that it wasn’t toxic to many cancer cell lines. 
As you said, in the small print it was clear that the majority of cells that were 
killed by recombinant TNF had been pre-treated with actinomycin D.137 They 
were killed because the cells couldn’t make all those protective molecules that 
we know so much about now. In fact, the idea that TNF was specifically toxic 
for malignant cells and not normal cells, and this was the reason why it was 
going to be such a successful treatment, was based on very flimsy evidence.
Walczak:  I think that is important, and you are absolutely right, Fran, that TNF, 
of course, turned out to be a molecule that is capable of driving gene activation 
more so than cell death. However, there are different signalling complexes that 
can drive either gene activation and cell death, and the first molecule that was 
cloned, which plays a role in TNF receptor signalling, was the receptor interacting 
protein 1 (RIP1), which is a kinase that was neglected at the beginning. So ‘RIP 
kinase 1’ was only called ‘RIP1’ throughout the literature since it was cloned, 
until a few years ago, when it turned out that RIP1 is a central molecule for 
the gene activation but also for the cell death arm that, when there is some 
perturbance in the gene activation, you can then get cell death. And what people 
hadn’t realized until a few years ago was that TNF-driven inflammation was 
always thought to be only driven by the gene activatory arm. 
People were trying to develop, as you mentioned, Marc, small molecule 
inhibitors and the nuclear factor kappa-light-chain-enhancer of activated B 
cells (NFκB) was one of the drivers of this TNF-induced gene activation, so 
people thought they’d be able to develop inhibitors of NFκB, or inhibitors of 
135 See note 49. 
136 Carswell et al. (1975).
137 Creasey et al. (1987) and Flick and Gifford (1984).
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Jun kinase (JNK), which is activated on another TNF-induced gene activatory 
arm, to treat inflammatory diseases. But that never really worked.138 
As it turns out, in many cases, you cannot block TNF-induced inflammation 
via the gene activatory arm. And that was, of course, a conundrum. It wasn’t 
until we showed a few years ago that if you have deregulated gene activation 
and at the same time get aberrant cell death in mice that are devoid of one 
of the components of the TNF receptor signalling complex, then you get an 
inflammation despite having less gene activation.139 So how does that work? 
We then showed that it’s in fact the TNF-induced cell death that is causative 
for TNF-induced inflammation.140 So rather than TNF-induced inflammation 
always being driven by the gene activatory arm, it’s now also clear that when 
you have some perturbation in the TNF-induced signalling that leads to 
aberrant cell death, this cell death can also result in an inflammation. That can 
be blocked, and now I’m coming back to the central molecule, by inhibiting 
RIP1 kinase. So right now the thought is, perhaps at least in diseases where you 
have RIP1 kinase-dependent aberrant cell death, that you could interfere with 
that arm of TNF-induced inflammatory processes by inhibiting RIP1 kinase. 
The first clinical trials are now happening with RIP1 kinase inhibitors that are 
being developed by GlaxoSmithKline (GSK)141 but also, of course, by a number 
of other companies. It will be extremely interesting to see how this will unfold. 
Maini:  For what indication?
Walczak:  I’m talking to different people at different companies about this but it’s 
clear that they would first like to go into more acute diseases but they also think that 
there is a possibility of going into the diseases where possibly TNF inhibitors work 
now. I think it remains to be seen whether there are two classes of autoimmunity, so 
to speak: one driven by TNF-induced aberrantly enhanced gene activation, where 
that class of drug probably wouldn’t work, and the other one driven by TNF-
induced aberrant cell death. So it could be that there are two aetiologies of TNF-
induced inflammation: one driven by enhanced gene activatory capacity, and one 
by aberrant cell death that happens. And possibly the RIP1 kinase inhibitors would 
only work in one arm, but that still remains to be seen. 
138 See, for example, Liedtke et al. (2002).
139 Gerlach et al. (2011).
140 Gerlach et al. (2011) and Rickard et al. (2014).
141 GSK is a pharmaceutical company that was established in 2000 through the merging of Glaxo Wellcome 
and SmithKline Beecham; http://www.gsk.com/ (accessed 22 March 2016). 
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There is a lot going on in this field right now. I recently organized, together with 
Peter Vandenabeele142 – who, of course, studied with Walter Fiers, whom you 
mentioned, Fran – the TNF conference in Ghent,143 and it was fascinating to see 
how alive TNF research is, not only on the cellular level in order to understand 
the signalling but also what we’re trying to achieve with new insights on the 
clinical side. Also, with other TNF superfamily members, of course, because 
what we haven’t spoken about so far today is that TNF is the founding member 
of a whole family of cytokines that, either if blocked, or by sometimes activating 
their receptors could be therapeutically very beneficial.144 It looks like this family 
is full of therapeutic opportunities that can still be harnessed a lot better than 
we’ve done so far, and today it appears that TNF was only the beginning.
Dr Marcos Vidal:  It is time also to mention the conundrum of TNF as a target 
and a therapy, and perhaps Fran could discuss whether your own work on the 
papilloma model, which two roles of inflammation seem to be more promising, 
and these kinds of parallels where TNF is actually required for tumour 
progression.
Balkwill:  Sure, yes, and also the fly work that maybe explains the conundrum 
a bit.145 
When we first got TNF from Walter Fiers, it did cause necrosis of tumours on a 
good day, there was no doubt. This was looking at the crude models we had at 
the time, which were subcutaneous xenografts, if I remember correctly. I think 
we published a first paper with Walter Fiers in 1987,146 and in 1988 I’d become 
very interested in ovarian cancer and, also, I felt that subcutaneous xenograft 
models were not the best model for cancer. We used to grow these xenografts 
intraperitoneally, and Saleem Malik, a clinical fellow in the lab, was doing a study 
of treating them with TNF, and we didn’t have any other way of really imaging 
the mice. We would take a few mice every week and look at what was happening 
to them, and what we found was quite extraordinary: that actually the TNF was 
142 Dr Peter Vandenabeele is a Group Leader at the Flanders Institute for Biotechnology (VIB), Belgium; 
http://www.vib.be/en/research/scientists/Pages/Peter-Vandenabeele-Lab.aspx (accessed 22 March 2016).
143 The 15th International TNF Conference took place in Ghent, Belgium (20–23 May 2015).
144 See, for example, Grewal (2009).
145 A reference to the work done on Drosophila melanogaster (common fruit fly), which Dr Marcos Vidal 
discusses on pages 59–61. 
146 Balkwill, Ward, and Fiers (1987). 
The Recent History of Tumour Necrosis Factor (TNF)
54
promoting a tumour microenvironment. In the control mice we would see many 
free-floating clumps of cells, but in the mice treated with TNF they’d develop 
a very complex tumour microenvironment; there’d be blood vessels, there’d be 
fibroblasts. TNF was stimulating a tumour microenvironment. So we published 
a paper in 1989 that I think was labelled ‘the paradoxical behaviour of TNF’, and 
there were other bits of evidence at the time countering the fact that TNF was 
killing cells.147 There were publications showing malignant cells could make TNF 
as well, which made some people scratch their heads. 
I think it was in 1993 that, using in situ hybridization, which was the best tool 
we had at the time, we showed that malignant cells in human ovarian cancer 
biopsies were making TNF.148 Then, the following year, if I remember correctly, 
we showed that macrophages in breast cancers also made TNF, and this is when 
the work was going on in RA down at the Kennedy Institute.149 I can remember 
going down there a lot and there were so many parallels. Therefore, we began to 
carry out experiments on the tumour-promoting effects of TNF, particularly in 
the tumour microenvironment. And then, when George Kollias had the TNF 
knockout mice, he agreed to send them to us before he published them, and 
then we did the skin carcinogenesis experiments.150 And the results were very 
clear. You could open up a cage and you knew which were the TNF knockout 
mice because they didn’t have a single papilloma. People who were working on 
the anti-tumour effects of TNF, were, I was told, devastated by the paper we 
published on this in Nature Medicine in 1999.151 
The other interesting thing was that if you looked at the skin of the mice that 
are treated with 7,12-dimethylbenz[a]-anthracene (DMBA) and promoted 
with 12-O-tetradecanoyl-phorbol-13-acetate (TPA),152 it stimulates a lot 
of inflammation and you get these papillomas that sometimes progress to 
malignant tumours. But the TNF knockout mice just didn’t get any, and their 
147 Malik et al. (1989).
148 Naylor et al. (1993).
149 Miles et al. (1994).
150 Professor George Kollias is a Member of the Academy of Athens and Professor of Experimental Physiology 
at the Medical School of the National and Kapodistrian University of Athens.
151 Moore et al. (1999). 
152 The so-called ‘initiation/promotion models’ of experimental carcinogenesis have been widely used to 
study skin tumorigenesis. In such models, a topical subcarcinogenic dose of a chemical (DMBA) is first 
applied to the back of the skin (initiation) followed by topical applications of one or more chemicals (TPA; 
promotion). For more details, see National Toxicology Program (1996).
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skin was incredibly smooth. I’ve always thought of anti-TNF as a skin cream, 
you know! I can remember going to Centocor and speaking to some people, 
and there was a very productive collaboration with Centocor who, I think, were 
very visionary in those days and really wanted to find other uses for anti-TNF. 
As you will remember, we were involved in three clinical trials, Phase 1 clinical 
trials of anti-TNF. 
Maini:  In ovarian cancer?
Balkwill:  Well, there was a Phase 1 all-comers, there was a small study, very 
much inspired by your work, looking at ascitic disease in end-stage ovarian 
cancer patients, and just looking to see if we could see changes in inflammatory 
profile and things like that. Then Martin Gore at the Royal Marsden Hospital 
did a study in advanced renal cancer, and that was very interesting.153 There were 
definitely partial responses in some patients. It’s a paper in the Journal of Clinical 
Oncology, 2007.154 But then Centocor became ‘Ortho Biotech Oncology’.155 I 
know some of the people who worked at Centocor said they felt they almost 
climbed to the top of Everest in testing anti-TNF in cancer but they never 
got to the final point. Now, of course, we all see wonderful things with the 
immune checkpoint blockade, but both in those trials and with an anti-IL-6 
trial that we did in ovarian cancer just a bit later, I do wonder what would 
have happened if we’d had the modified ‘Response Evaluation Criteria In Solid 
Tumors’ (RECIST)156 – I don’t know if you all know this, but the RECIST 
criteria in Phase 1 or 2 clinical cancer trials are that if a tumour size increases by 
25 per cent, then you have to stop the treatment and the patient’s disease is said 
to ‘progress’. But once they started immune checkpoint blockade somebody 
in the States had the courage to say, ‘Hang on a minute, maybe the tumour is 
getting bigger because it’s filling with good lymphocytes.’
153 Martin Gore is Professor of Cancer Medicine at the Institute of Cancer Research and a Consultant 
Medical Oncologist at the Royal Marsden Hospital. For more details, see https://www.royalmarsden.
nhs.uk/our-consultants-units-and-wards/consultant-directory/professor-martin-gore (accessed 16 March 
2016).
154 Harrison et al. (2007). 
155 See note 80.
156 The RECIST criteria are a set of published rules (published in 2000 and updated in 2009) that define 
when tumours in cancer patients respond, stabilize, or progress during treatment. For the latest version of 
these criteria, see Eisenhauer et al. (2009).
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Walczak:  That was Jim Allison telling the clinicians, ‘You have to keep on going 
because they’re filling up with lymphocytes, you have to go on!’ 
Balkwill:  And so now there are immune RECIST criteria where if a tumour 
starts growing a bit then it’s not necessarily a sign to stop the treatment, if the 
patient is feeling well and there are other indications of response. Responses 
were nowhere near as dramatic as immune checkpoint blockade, but there were 
certain biologic effects of the anti-TNF and the anti-IL-6, and I was encouraged 
earlier on because a question for the rheumatologists was there must have always 
been a worry: how could you give anti-TNF to patients without inducing 
cancer? Many people said, ‘Ah well, this anti-TNF stuff, it causes lymphoma’ – 
that must have been one of the hurdles, you didn’t mention that?
Maini:  I think it required what we call ‘post-registration data’, and what has 
happened is that there are a number of registries in the world now. There’s one 
in the UK, there are very good ones in Sweden, Spain, and the USA, where, 
basically, patients who are treated with anti-TNF are followed up to see whether 
the incidence of side-effects is any higher than expected in the general population. 
What’s turning out to be the case in RA is that the incidence of lymphomas is 
no different, and may even be a bit less, in anti-TNF treated patients than in 
the RA population not on anti-TNF treatment. That’s been very reassuring as 
there is still a question mark over this issue, because if you look at the data there 
is some evidence that the very high doses of anti-TNF might be associated with 
a lymphoma, especially in childhood diseases. So there is some residual concern 
about the association with an atypical type of lymphoma. 
Balkwill:  Yes, a gamma delta T cell lymphoma, isn’t it?
Maini:  I think an alpha beta T cell lymphoma can occur in children, and this 
has occurred so rapidly after anti-TNF treatment for childhood RA that there 
may still be a significant risk there. It’s not completely clear, but I think the 
other reassuring thing that’s emerging from these registries is that RA itself 
is a predisposing factor for lymphoma, and there’s a 28-fold increase in the 
incidence of lymphoma in severe RA. So, as patients with less severe disease 
are being treated with anti-TNF we are not seeing lymphomas now because 
it’s less likely to occur anyway in that population. The story is becoming more 
clarified, and since anti-TNF is now being used in the minimal possible dose, 
rather than in massive doses, and when used with methotrexate, it really is 
possible to titrate a dose of the anti-TNF agents to much lower doses and get 
prolonged effects. 
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Walczak:  Mentioning the registries it would be interesting to ask given your data, 
Fran, on the anti-TNF therapies in the pre-clinical models: what has actually 
happened in the patients who have been suffering from different autoimmune 
diseases and have been treated with anti-TNF therapy with respect to colon 
cancer or other inflammation-driven cancers?
Maini:  I think data from the British registry and the Swedish registry, I don’t 
want to misquote, and the Germany registry might answer that. I think there’s 
a diminution in the incidence in some of these cancers, right?
Kalden:  It’s not yet statistically significant but there is a diminution, definitely 
in nearly all cancers – also in colon cancer – with one exception; that is 
basaliomas.157 There is a discussion going on about how solid this finding is. In 
patients undergoing medication with TNF blockers, all together, none of the 
registries in Europe have observed a significant increase in malignancy, with the 
exception of basaliomas, even over a long period of time.
Maini:  Which cancer is that?
Kalden:  Skin cancer/basaliomas. The mechanism behind the diminution could 
be the decrease in inflammatory activity but again further data are needed of 
other malignancies.
Walczak:  So the question I asked, of course, is because it would be interesting 
to see whether there is a reduction in certain inflammation-associated cancer, 
and, if so, how patients still develop cancer? Under anti-TNF therapy, is their 
immune infiltrate altered in a way that would make it more likely for a cancer 
immunotherapy to work? If so, that could suggest that anti-TNF therapy could 
be combined with anti-programmed cell death protein 1 (PD1)158 or anti-
cytotoxic T lymphocyte-associated protein 4 (CTLA4)159 therapies in order to 
enable the right inflammation to happen in the cancer rather than the wrong 
one. You mentioned previously that prostaglandin expression can be driven by 
TNF, and, of course, there’s also very good evidence that aspirin, which inhibits 
production of prostaglandins, works very well to prevent, for example, colon 
cancer. There’s a lot of room to look into these things apart from the benefit 
157 Basalioma (or basal-cell carcinoma) is a frequently encountered malignant skin tumour of low metastatic 
potential.
158 PD1 is a cell surface receptor that downregulates the activation of T cells and, thus, prevents the expression 
of autoimmunity.
159 CTLA4 is a cell surface receptor that prevents the activation of T cells.
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achieved in the treatment of autoimmune patients when we look with the right 
questions at these registries. That way we could already learn a lot about the 
possible use of TNF blockers in cancer therapy.
Balkwill:  I agree. I had a review out in Nature Reviews Clinical Oncology two weeks 
ago discussing the ongoing clinical trials targeting cancer-related inflammation, 
reviewing the anti-TNF, anti-IL-6, and many other approaches but also 
suggesting that the way forward is to do the anti-inflammatory treatments and 
then other immunotherapies that target the adaptive immune system.160 I think 
it’s something we’re certainly working on, and others as well. 
Chernajovsky:  But the principle by which TNF has worked at the peak of the 
cytokine cascade has never been shown in cancer, so targeting TNF may not be 
necessarily the best treatment?
Balkwill:  Oh no, I don’t think anyone would say that targeting TNF in cancer 
is the best treatment, but it is a major mediator of cancer-related inflammation, 
as is IL-6. I think the difference between malignant disease and autoimmune 
disease in terms of anti-TNF or anti-cytokine treatment is that the autoimmune 
disease is really more stable, whereas the driver for the abnormal production 
of the cytokines in a malignancy is the malignant cell itself. It’s not the 
microenvironment, and the malignant cells just overcome the inhibition 
because they can evolve and escape. If you inhibit with anti-TNF it will make 
IL-6, or whatever, and I think that’s the difference. 
Feldmann:  There was one clinical trial that was an outlier, which was a six-
month anti-TNF trial in chronic obstructive pulmonary disease, and there 
were four lung cancers that emerged. That’s really very interesting because 
four cancers in six months really suggests that they had started before but they 
weren’t clinically overt. There’s now literature that inflammation is also involved 
in the metastasis process, so, for example, p38 mitogen-activated protein kinase 
(MAPK) inhibition upregulates metastasis in a number of models of cancer. So 
it’s a very fine balance which we don’t understand at the moment. 
Maini:  I’m just reminded about checkpoint inhibitors for cancer. CTLA4 
antibodies and PD1 antibodies induce autoimmunity, and one of the very 
unpleasant side-effects is the induction of ulcerative colitis type disease, and 
that has been treated by anti-TNF successfully. 
Balkwill:  It’s a good point, yes, a very good point. 
160 Crusz and Balkwill (2015).
The Recent History of Tumour Necrosis Factor (TNF)
59
Saklatvala:  I was just going to say that TNF might be a tumour promoter, since 
it is biologically very similar to phorbol ester, which, of course, is historically 
probably the oldest tumour promoter and still used experimentally.161 But 
presumably you need to know in any particular cancer to what extent the 
inflammation is promoting the tumour and to what extent that inflammation is 
TNF-driven, and that’s very difficult. 
Balkwill:  Yes, and it varies from cancer to cancer. I think really we’d like to hear 
from Marcos now but just to follow up in the context of this meeting, we got a 
result a couple of weeks ago that I’m now putting into a paper that we’re going 
to submit soon. We were looking at the effects of neoadjuvant chemotherapy in 
patients with high-grade serous ovarian cancer to see if it changes the immune 
landscape because then you can go with immunotherapy. To cut a long story 
short, we did lots of things and there were very interesting effects on T cells, 
but, of course, I also wanted to look at TNF. When you give a patient the 
average neoadjuvant chemotherapy, the TNF levels in the plasma, which are 
much higher than they are in normal people, just go. It doesn’t matter if they 
have a good response or a bad response to neoadjuvant chemotherapy, the TNF 
levels go right down. But what was absolutely lovely to me is that when we 
grind up the metastasis from the patient – metastasis from the patient removed 
at surgery after the chemotherapy – in the plasma, compared with pre-tumour 
patients, the TNF levels are absolutely rock bottom. And we looked at IL-6 and 
interleukin-8 (IL-8), and other cytokines, and it’s only TNF that really fell after 
chemotherapy, which really pleased me.
Vidal:  To go back to Jeremy’s point on tumour-related inflammation or 
promoting or suppressing tumours, that’s work that we attempted to clarify 
using the fruit fly, Drosophila melanogaster, which is a much simpler system. 
What we found is that TNF signalling perhaps arose in evolution as an epithelial 
proofreading mechanism. When you have epithelial cells that lose polarity, 
the apical-basal polarity that they normally have, the haemocytes, which are 
Drosophila’s macrophages, are recruited to that site, they produce Drosophila 
TNF, which in this context is an apoptotic factor. If you block the Drosophila 
macrophage or TNF, the cells that lack polarity will develop into tumours but 
these tumours will be local, they will not be invasive. 
161 Phorbol esters act as tumour promoters through activation of protein kinase C. For more details, see 
Blumberg (1988). The most widely used phorbol ester for the induction of carcinogenesis is TPA; see 
note 152.
The Recent History of Tumour Necrosis Factor (TNF)
60
We found that a second hit to the system, in this case the Ras oncoprotein, 
would allow the malignant cell to hijack TNF coming from the haemocyte, 
from the macrophage, and then diverted it. Instead of a tumour cell death, this 
is led into an invasive programme, and it will start producing collagenase and 
a lot of acting dynamic changes that allow the cell to disseminate. So in that 
context we have genetically identified which are the components that will dictate 
whether this kind of inflammatory response will be suppressing or promoting.162 
Walczak:  We found these data highly exciting and very interesting. Of course, 
we have to remember that in Drosophila, the family of TNF molecules is a lot 
smaller – there’s only one – whereas in humans and other mammals, including 
mice, we have a lot more. So there may be a distribution of the workload 
between different TNF superfamily members with the different aspects that 
you’ve just mentioned. In that respect, it’s interesting to note that for two TNF 
superfamily members – which are very similar to TNF – the FAS ligand163 
and the TNF-related apoptosis-inducing ligand (TRAIL), have been shown, 
in contrast to TNF, to indeed induce tumour cell death. However, when the 
cell has begun to be transformed and when you then add further mutations, 
like KRAS mutations164 – we have basically used the same nomenclature, or 
the same wording as you, Marcos – the pathway can be hijacked so that now 
the tumour cell makes use of the CD95/CD95 ligand or the TRAIL/TRAIL 
receptor system to its own advantage in enhancing the growth and invasiveness 
of these cancer cells. In this situation, it’s also not only good to block TNF but 
what we’ve shown is that in some cases it’s good to block the CD95 ligand and 
in others to block TRAIL. In the case of the CD95 ligand, this can be achieved 
with an antibody to the CD95 ligand or with a CD95-Fc fusion protein, which 
has, in fact, been tested in patients with glioblastoma multiforme, together with 
irradiation, and has shown clinical efficacy in these patients.165 With respect to 
TRAIL, we’ve recently shown that inhibiting TRAIL can, in fact, be beneficial 
in mice – we have used a KRAS-driven model both in the pancreas and in the 
lung – that in these situations the endogenous TRAIL/TRAIL receptor system 
is required for cancer cell invasiveness.166 When we remove the TRAIL receptor 
162 Cordero et al. (2010).
163 See note 86.
164 KRAS mutations are associated with several types of cancer.
165 See, for example, Wick et al. (2014).
166 von Karstedt et al. (2015).
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genetically from the cancer cells, the outcome is the same as if we had taken 
away mutated KRAS. So the entire increase in invasiveness and aggressiveness 
of the cancer cells endowed by mutated KRAS was neutralized when taking out 
only the TRAIL system in these cancers. I therefore think that the concept that 
was first shown for TNF and for which you have then shown very nicely how 
it actually works in Drosophila, Marcos, can be extrapolated into the CD95 
system in certain cancers, and into the TRAIL system in others. This means that 
there is an expansion of the effects that were first observed for the TNF system 
into at least two additional members of the TNF superfamily. 
Vidal:  That’s very interesting, how conserved these systems are in evolution, 
and a future challenge that I think will be interesting in the mammalian 
system is the cell biology of the ligand and the receptor because what is also 
interesting in Drosophila is that the TNF receptor is very focalized at the apical 
domain of epithelial cells. That perhaps suggests a mechanism by which the loss 
of polarity will delocalize a receptor and allow them to be recognized by the 
immunosurveillance cells. 
Balkwill:  Making the discussion a bit more general, what does everyone think 
the main role of TNF is, whether it’s in the fly, the mouse: why do we have 
TNF?
Feldmann:  It’s a fire alarm. 
Balkwill:  Ah, you think it’s a fire alarm?
Figure 13: Dr Marcos Vidal (left) and Professor Joachim Kalden (right)
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Feldmann:  It’s the quickest cytokine to be produced in any injury, so whether 
it’s ultraviolet light, burns, immunity, you get a rapid induction of TNF, which 
coordinates leukocyte recruitment, so it’s a fire alarm. 
Kalden:  If you look at the phenotype of a TNF knockout, I think they are living 
quite a nice life. 
Walczak:  Well, if these mice had to live on the London tube they probably 
wouldn’t anymore because we’re endemic for certain diseases there that they 
would die of. We have to look at it from an infectious disease perspective 
and obviously without TNF you have a lot of problems with facing life when 
you’re exposed to everything that our predecessors in evolution have been 
exposed to.
Balkwill:  Do you think it’s a possibility – this is my own pet theory – that TNF 
might be a fire alarm in the young, and maybe even the middle aged, but in old 
age it’s a grim reaper? 
Williams:  I think it’s a fire alarm but I also think that it’s a feedback mechanism, 
and that, like many pro-inflammatory mediators – prostaglandin E
2
, for example 
– they induce localized inflammation, then feed back and suppress the immune 
response, suppress T cell responses. I think that TNF induces inflammation but 
then feeds back on the immune system to dampen down the immune response, 
which is driving the whole process. 
Chernajovsky:  Are my memories right or am I getting really old: the knockout 
mice, they didn’t have proper lymphoid organs?167 The structure was not right. 
Balkwill:  Yes. 
Chernajovsky:  It was just lymphotoxin? In lymphoid organogenesis they are 
very important, not just as a mediator of inflammation in adults. 
Maini:  There is a researcher at McMaster University called Dawn Bowdish.168 
Dawn worked in Oxford before, she’s a Canadian, and she’s back in Canada 
167 Professor Chernajovsky noted: ‘TNFα knockout mice completely lack splenic primary B cell follicles 
and cannot form organized follicular dendritic cell networks and germinal centers.’ E-mail to Dr Apostolos 
Zarros, 25 March 2016. For more details, see Pasparakis et al. (1996).
168 Dr Dawn Bowdish is Associate Professor at the Department of Pathology and Molecular Medicine of 
the McMaster Immunology Research Centre, Hamilton, Ontario, Canada. For more details on her research 
activity, see http://fhs.mcmaster.ca/pathology/contact_us/faculty/faculty_bios/bowdish.html (accessed 16 
March 2016). 
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now. When I was visiting her laboratory recently, she showed me some very 
interesting data on TNF knockouts. Basically, it is an anti-ageing phenotype. So 
she has what she calls ‘TNF sleek’ mice, or ‘TNF knockout sleek’ mice. 
Balkwill:  Yes, it’s just like the skin cream because we used to say the skin of the 
TNF knockout mice was as smooth as a baby’s bottom – that was the term that 
came from the animal house. The TNF knockout mice were indeed ‘sleek’ mice. 
Maini:  I don’t want to misquote her because I haven’t seen her work in print, 
and I don’t think the anti-ageing thing is published yet. I think she shows 
some quite important lack of a protection, in these knockout mice, that there 
wasn’t any undue susceptibility to certain infections, which is surprising for me. 
We know that tuberculosis infections are increased, so intracellular infections 
are increased, but it was by no means established that extracellular bacteria 
infections are increased in these patients. 
Balkwill:  There was also that paper on the brain, I think in Nature, on sensing 
aging in the brain and TNF produced in the brain.169 
Tansey:  I just wonder whether I could ask you to reflect, in the final half hour, 
on some broader historical themes. It’s absolutely fascinating, this scientific 
discussion, but we are here to discuss the history of TNF and we want to try 
and get behind the papers, the published papers, and I wondered if I could 
ask you, these may be irrelevant questions but I don’t think they are: what 
kind of networks were important; what kind of societies and clubs; where 
did you talk about your papers; how did you all get to know each other? 
Because this is a new field, this is not necessarily the Physiological Society nor 
the Biochemical Society, for example. Who funded this work? We’ve heard 
about some funding, and of particular companies: where was the MRC or 
the Wellcome Trust, or any of these kinds of organizations? And institutions? 
We’ve heard quite a lot about the Kennedy Institute, and some companies. 
Were they unique? Were they the only organizations? We’ve heard a little 
about opposition: again, may I ask if you could just reflect and perhaps say 
something on those issues?
Walczak:  Tiny and Joachim, you both mentioned the weekend you spent 
together in your house discussing…
Kalden:  Only one weekend. 
169 Zhang et al. (2013).
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Walczak:  I know, but, I think that would be important to mention in this 
context, right? These personal connections are important in all walks of life, 
including science. 
Kalden:  I think it is always important, and this is reflected, for example, by 
the German Research Foundation.170 They are putting money into networks in, 
say, B cell physiology, pathophysiology, getting different good centres together, 
even some centres working in Austria or in France. Bavaria has established an 
immune-therapeutic network where all five university hospitals are included. 
New therapeutic pathways will be explored using cell therapeutic approaches 
as well as different antibody constructs and small molecules. It is hoped that 
these networks will get into a fruitful cooperation with the pharmaceutical 
industry. Industry should be interested specifically in financing clinical trials. 
Neither the German Research Foundation nor the Ministry of Science and 
Technology really have the financial situation to finance huge clinical trials. It 
would be interesting to see how the interaction between university institutions 
and respective pharmaceutical industries are going in other countries.
Balkwill:  But back then, as we were talking about the 1980s, it was really the 
company-sponsored money that funded the clinical trials?
Feldmann:  I think the role of companies is both a plus and a minus. Sometimes 
it’s positive, but at the moment the willingness of companies to invest in 
anything that looks like research is not too high. But to go back to Tilli’s 
question: what were the important networks? Well, I mentioned already setting 
up the cytokine meetings, so Jo Oppenheim was very important.171 There are 
cytokine societies that have struggled to survive that end up merging between 
the Cytokine Society and the Interferon Society – one survivor was better than 
two lame ones.172 The TNF meetings have been very important in driving the 
field, and I think part of my contrary view to the role of industry is based on 
having run one of these meetings, as did Henning,173 yet the Pharma companies 
170 The Deutsche Forschungsgemeinschaft; see website at http://www.dfg.de/en/ (accessed 16 March 2016).
171 For Dr Joost (Jo) J. Oppenheim, see note 59. 
172 The ‘International Cytokine and Interferon Society’ was a merger of the ‘International Cytokine 
Society’ and the ‘International Society for Cytokine and Interferon Research’ in 1987; see http://cytokines-
interferons.org/About-ICIS/Constitution-and-Bylaws/ICIS_ByLaws_Final.aspx (accessed 22 March 2016).
173 Professor Henning Walczak commented: ‘the series started with the TNF meeting in 1987 in Heidelberg 
[…] the latest one (the 15th in the series) was organised by myself and Peter Vandenabeele in Ghent, 
Belgium, in 2015, and the next one in this biannual series will take place in Singapore in the spring of 
2017.’ E-mail to Dr Apostolos Zarros, 27 May 2016. 
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are selling almost 30 billion dollars of anti-TNF but they will give you nothing 
to support the meetings from where the material that led to these sales came. 
The companies will not give you the value of a single patient’s therapy to help 
feedback into the academic base. 
[Unidentified participant]:  It’s a little bit different with the ‘Advances in 
Targeted Therapies’;174 that is a meeting we are running now for 20 years, and it 
is both inclusive of basic and clinical science. 
Feldmann:  We could argue the academic networks are important but I think 
it’s the informal ones that matter, and they are driven through relatively small 
meetings where you can find each other. But the biotech industry in its first life 
was very much more academic. They were really academics who had somehow 
raided the bank: Genentech, Immunex, Amgen, and others, were behaving like 
super universities doing exceptionally good research; they cloned most of the 
cytokines, and shared the reagents generously. This is no longer the case. 
Balkwill:  I would agree with that; I think the biotech industry was very 
instrumental in research. In the UK, I think also interactions between cancer 
researchers and those working on infections and inflammatory diseases were 
important. Do you remember the British Cytokine Group (BCG) that Fionula 
Brennan and I ran for a long while?175 Audiences were about 100 people and 
maybe one international speaker, and that was really good. That came out of the 
TNF meeting in Heidelberg in 1987,176 where I realized that there were a lot of 
people working on TNF in other diseases, not just cancer, and that was really 
useful for quite a few people. It sort of faded after a while.
Kalden:  It was a meeting which was organized by Daniela Maennel and 
colleagues, if my memory serves me correctly.
Balkwill:  Yes, that was the one in Heidelberg. But there were two meetings in 
Heidelberg. There was a very early one. 
Kalden:  I believe one of the organizers was Holger Kirchner. 
Balkwill:  The TNF meetings, I agree, but I think in the UK the BCG was 
useful; we ran it for about ten years, if not longer. I would say also organizations 
174 The proceedings of the ‘International Symposium on Advances in Targeted Therapies’ (I–XIV) are 
published as Supplements to the Annals of the Rheumatic Diseases (1999–2013).
175 For more details, see Balkwill and Burke (1989).
176 Bonavida et al. (1988). 
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like Cancer Research UK that renewed programme grants, and presumably the 
Arthritis and Rheumatism Council was another one.177
Maini:  So, Tilli, if I go back to focusing on the anti-TNF story and the funding: 
the funding came from multiple sources, and I think Marc and I were faced 
with challenges throughout. I think all the researchers were quite inventive in 
raising money and diverting money in various directions that weren’t necessarily 
intended by the person giving you the money. So there’s no doubt that the 
Kennedy Institute funding was by the Arthritis and Rheumatism Council, now 
known as Arthritis Research UK. They gave money – I was the Director of 
this institution. It allowed me to recruit Marc and his group into the funding 
stream; that helped. But, actually, when it came to the crunch, the referees to 
whom we submitted our anti-TNF story weren’t enthusiastic about it and the 
funding had to come mainly from our industrial grants, but also from Fellows 
who came to work with us with their own funding. For example, there was 
an Australian chap called Mike Elliott who came to work with Marc and me 
from Melbourne, from the Walter and Eliza Hall Institute178. He had worked 
with the haematologist Don Metcalf there, but wanted to do clinical work, and 
although he had never done any clinical trials in his life, we involved him in 
the trials because he’s highly intelligent. It was very useful having a very good, 
motivated, hardworking Aussie in our group who could actually be present for 
recruiting and managing the patients for our initial trials. That funding came 
from the Australian Rheumatism Association or the Australian MRC; perhaps 
both of those. The Nuffield Foundation gave us some money for some minor 
part of our work, a small project grant, I think. We had several little grants that 
were being put into the kitty, ultimately leading to these big trials, which were 
entirely funded by Centocor. 
Kalden:  Could I just make clear what I was saying: funding of research in 
Germany is really fantastic. This is why research is developing very well, both in 
basic- and more clinical-related activities. In this respect, it is worth mentioning 
that basic science is nowadays also performed in clinical institutions, so we are 
coming up with data from basic institutes in clinical as well as in basic science. 
The question is, really, which institutions will take up this data for further 
investigations? In order to translate some of these data into clinical practice, I 
believe that the help of pharmaceutical companies is needed. 
177 See note 11.
178 See note 24. 
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Walczak:  I would like to touch upon a different point with respect to the 
history of modern biomedicine and the role that the companies like Genentech 
and Immunex have played, at least in the field we have been talking about – we 
mentioned these names throughout. They could exist at the time when they 
were founded because they were experiments for venture capitalists that had 
worked. In the meantime, many other experiments that were supposed to be 
based on the Genentech and Immunex principle, and Biogen and DNAX for 
that matter, have been carried out, and there were only a few additional ones 
that were really as successful as Genentech, Immunex, and Amgen, so these 
experiments, these few experiments from the venture capitalist standpoint, have 
worked. That’s why there was this ‘playground’, as Steve Gillis, the founder and 
first Chief Executive Officer of Immunex, used to call it; even though he was 
probably also behind one of the things that was mentioned here before. I joined 
Immunex after he had left, but still benefitted from the ‘playground’ he had 
left behind. You could see how it worked, that there was this group of, I would 
say, top scientists in the field of immunology at the time that were gathered on 
a theme, and they would work without having to worry about grant money 
because no one there was worried about any grant, simply because you didn’t 
need grant money. There was enough money to do anything you would like to 
do; we came in as postdocs and we could do what we wanted to do. There was 
no restriction whatsoever on what we wanted to do, on what we could have 
done. It’s important to mention that this type of biotech industry does not 
exist anymore today. The reason is that in the investment banks of today where 
mathematicians analyse the pharmaceutical industry and the biotech firms, the 
people who are making the calculations think that the entire biotech concept 
hasn’t worked. I would counter argue that the concept has worked but that you 
need the right brains behind these concepts. 
Genentech and Immunex were very different from many of the other companies 
because they did not have a high degree of mediocrity in these institutions. They 
had very many of the world’s leading scientists in their respective fields. I still 
believe that the concept of putting roughly 50 million euros, dollars, or pounds 
a year into the best science in a particular field will be able to yield something 
similar to what turned out to be the 10 billion that Amgen paid for Immunex 
16 years after it was founded. I am convinced that concept would still work but 
you need to get the right people into this concept, on both the scientific and 
investment side. Unfortunately, the people who come up with all the important 
questions that decide on whether an investment will happen or not have taken 
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into account too many of the mediocre companies that didn’t work, so they say 
the concept hasn’t worked. But I argue that it does work, you just need the right 
quality and critical mass of excellence. 
Chernajovsky:  What I want to say is that all the work on anti-TNF has been 
exemplary for many other disciplines in medicine, and it’s not just Fran who 
has been looking at the work of Tiny and Marc with admiration and trying 
to follow it up from the cancer perspective. The people who work with MS 
have done the same, and all the biological registries that were established to 
follow up on the patients who were treated with anti-TNF and biologicals were 
exemplary to many other disciplines. This story is not only about the success 
of the anti-TNF trials, it’s the success of how to approach a medical problem 
and to deal with it with the most modern medicine that you can. The fact 
that, as of course as we know, times have changed and there were a lot of good 
things happening in the 1980s, and late 1970s, because if you cloned a gene a 
company would be knocking on the door of the lab asking, ‘Hey, can we have 
it?’ That doesn’t happen anymore. So things have changed a lot but all this work 
has been absolutely instrumental to show how to progress a project in medicine. 
Maini:  I just want to comment that our work at the Kennedy Institute was 
unusual in that we were able to take it from the very beginning to the very end, 
to registration.179 Now, there are many reasons why this became possible, but 
we were involved at every stage of it, including the Phase 3 trials. I think that a 
lot of work in translation gets stuck at some stage or another because there isn’t 
the continuity of input. That’s a serious problem. You can see, for example, that 
companies are producing lots of new molecules, including therapeutic molecules 
and targets, and academics are producing quite interesting information on 
pathogenesis and possible candidate molecular targets, but it’s sort of getting 
stuck somewhere along the line of development up to about Phase 1. After 
that, there isn’t the input or the insight, or collaboration, of the sort that is 
needed between scientists and clinicians and industry to actually talk and work 
without barriers. Many of us who get asked to talk to industry, for example, 
will find that you go and talk to them, and you never know what happened 
to that conversation. It kind of disappears into the ether, there’s no feedback, 
and there’s a lot of confidentiality involved with it. And so, it was the age of 
innocence that Marc and I enjoyed where we could actually talk freely about 
what we did, without thinking too much, frankly to our detriment, because we 
could have patented some of the stuff that we did, which we didn’t patent. 
179 Feldmann and Maini (2003).
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That kind of culture, sadly, has also been asphyxiated by the imposition of 
bureaucratic structures, and I personally think that these networks that are being 
set up by, for example, the National Institutes of Health (NIH), by Germany, 
and in the UK, aren’t going to work because they don’t have the chemistry 
of the individuals involved. They are going to be completely sterile. There is 
an immune network in the USA that we know has had quite a lot of NIH 
money, but it’s got absolutely nowhere. They have done some trials in insulin-
dependent diabetes mellitus with anti-CD3. They saw the expected Epstein-
Barr virus infections and so didn’t go very far, they didn’t produce anything very 
novel, and I think that network has folded. 
Feldmann:  It’s still going but it hasn’t produced anything. I think if we’re talking 
about facilitators and inhibitors of progress, I’ve alluded to the age of innocence 
when there were no MTAs, but, actually, I think in British science – and I don’t 
think it’s any better in America where I spend a bit of time, and I don’t know 
about Germany – the fixation of universities and other organizations on trying 
to file patents to cover the miracle of some discovery, of making money, is a real 
impediment to science. 
When I was at Imperial College and our Institute was getting significant royalties 
and I was involved in management, we got little memos of how much the 
Imperial tech transfer office generated in cash. So in a good year they generated 
three million pounds. You can guess what they cost. Every year they ran at a loss. 
But the loss to scientific productivity has been monumental because every time 
you wanted to borrow somebody’s reagent it would take you six months, and 
probably meant that at least half the things that you wanted to do got stopped. 
In the history of modern biomedicine, a very interesting topic to focus four 
hours on might be the patenting system: the pros and cons. Is the licensing 
system fit for purpose? I don’t think it is. 
Having been involved in one of the few discoveries that’s made a lot of money, 
we know how many there are: in the UK it’s less than one every ten years. So 
for the lottery effect, we have this enormous albatross that academia is carrying. 
Now I could go on and on, but I think I’ve said enough. I think if we’re interested 
in what’s funded and what’s hindered, then I think at the moment we have a 
very strongly negative delusion about the capacity of academic research to find 
things worth patenting. And the NHS is even worse; the NHS set up offices 
to patent what it does. I’ve had visits from these people, but I’d better not say 
anymore. 
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Balkwill:  Well, the wine is ready so closing comments maybe slightly on a more 
positive note? [Laughter]
Woody:  Could I make a quick comment?
Balkwill:  Oh please, Jim! We’d love to hear from you. 
Woody:  My congratulations to all the people who have helped allow the larger 
anti-TNF story to emerge. We have to take some pride in the fact that, as Marc 
has pointed out, there are no patients with RA left in wheelchairs because of 
this class of drugs. It’s rare to have a clinical breakthrough of that gravity, so 
my congratulations to everyone on this list who participated; it was a great 
achievement. Thank you. 
Balkwill:  Thank you very much, and thank you for being there all the time. Is 
there anything else, Jim? We’ve not really given you too much of a voice, and 
yet I think your part was very critical. Is there anything else that you want to say 
before we finish? We can’t offer you a glass of wine, sadly. 
Woody:  We also had other trials; we looked at TNF distribution and found 
that it was distributed in a lot of different tissues. As I noted earlier with the 
anti-CD4 trials, we stopped them as they were clinically ineffective. We tried 
anti-TNF in MS, which actually made the patients worse, which was an issue 
when Roche/Genentech treated a number of MS patients with lenercept180 – it 
actually made quite a few patients worse. It is unclear why that happened. So 
we did a lot of other things, but the fundamental discovery that our anti-TNF 
was clinically beneficial to patients with RA, Crohn’s disease, and psoriasis were 
the pivotal achievements of this whole project. 
Tansey:  Well, that’s been a fascinating afternoon, thank you all very much indeed. 
I’m actually a former neuroscientist, and some of the things you were talking 
about reminded me of the 1980s when every time one picked up a fresh issue 
of Trends in Neuroscience there was a new molecule that was bioactive, there was 
a new receptor that had been found, and we had very good relationships with 
pharmaceutical companies in those days. What was very important was a point 
that was made early on: pharmaceutical companies made the tools of the trade 
for us; they made the drugs that we could then use for further experiments. 
That was very, very important. 
180 See note 108.
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You might be surprised, or perhaps not surprised, to learn that some of the 
comments that came at the end of this meeting are very common at some of 
these meetings. 
I’m particularly grateful to Fran, of course, for chairing the meeting, participating 
and being one of the people who suggested it in the first place. So thank you 
very much, Fran. 
Balkwill:  Well, I did nothing, it was Tilli’s team. I’ve thoroughly enjoyed it; I’m 
just so glad that the seminar finally happened. 
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Appendix 1
Timeline of important events in the history of TNF181

















discovery of  TNF
TNF and cachectin are identified as identical
first clinical trials of  TNF 
in advanced cancer
cloning of  TNF genes 
(both human and mouse)
TNF knockout mice prove resistant 
to induced skin carcinogenesis
TNF recognized as a therapeutic target 
for advanced renal cancer
development of  first 
TNF knockout mouse
cloning of  TNFR2
first clinical trials of  TNF 
antagonists in cancer
first trial of  cA2 in RA
first placebo-controlled trial 
of  cA2 in RA
infliximab (Remicade®) gets first 
FDA approval (for Crohn’s disease)
etanercept (Enbrel®) gets first 
FDA approval (for RA)
adalimumab (Humira®) gets 
first FDA approval (for RA)
R. N. Maini and M. Feldmann win the 
Albert Lasker Award for Clinical Medical Research

The Recent History of Tumour Necrosis Factor (TNF) – Appendix 2
75
Appendix 2
Simplified overview of the main biological actions of TNF  
in rheumatoid arthritis182
182  Illustration devised by Dr Apostolos Zarros based on data from: Feldmann (2009) and Dayer (2002).
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Appendix 3
Overview of TNF inhibitors mentioned in the  
current Witness Seminar transcript183
Drug Trade name (current 
company)
Description and indications (with dates 
of FDA approval)
Infliximab Remicade® (Janssen Biotech) chimeric (mouse and human) anti-TNF 
monoclonal antibody
Crohn’s disease (1998), RA (1999), 
ankylosing spondylitis (2004), ulcerative 
colitis (2005), psoriatic arthritis (2005), 
psoriasis (2006)
Adalimumab Humira® (AbbVie) human anti-TNF monoclonal antibody
RA (2002), psoriatic arthritis (2005), 
ankylosing spondylitis (2006), Crohn’s 
disease (2007), psoriasis (2008), juvenile 
idiopathic arthritis (2008), ulcerative colitis 
(2012), hidradenitis suppurativa (2015)
Etanercept Enbrel® (Amgen/Pfizer) fusion protein that fuses TNFR2 to the 
constant end (Fc) of an IgG1 antibody
RA (1998), juvenile idiopathic arthritis 
(1999), psoriatic arthritis (2002), 
ankylosing spondylitis (2003), psoriasis 
(2004)
183  Table devised by Dr Apostolos Zarros based on data from: Shealy and Visvanathan (2008) and Kalliolias 
and Ivashkiv (2016).
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Adaptive immune disease
Disease resulting from dysfunction 
of the adaptive (or acquired) 
immune system; an autoimmune 
disease.
Antibody
Protein of high molecular weight 
that is synthesized by B cells 
following stimulation by an antigen 
in order to react specifically against 
the latter; immunoglobulin. 
Autoimmune disease
Disease characterized by 
autoimmunity.
Autoimmunity
Pathophysiological state caused 
by a cell-mediated or humoral 
immunological response to antigens 
of one’s own body.
B cells
Type of lymphocytes that bear 
antigen-binding antibodies on their 
cell surface, have antibody secreting 
properties, and/or secrete cytokines. 
B cells mature in the bone marrow. 
Also known as B lymphocytes.
Basalioma
Frequently encountered malignant 
skin tumour of low metastatic 
potential; basal-cell carcinoma.
Chimeric antibody
Synthetic (recombinant) antibody 
that is actually a fusion protein, 
created through the joining of two 
or more genes that originally coded 
for different proteins.
Clone
Aggregate of genetically identical 
cells or organisms produced by a 
single progenitor cell or organism.
Cluster of differentiation (antigen 
nomenclature)
Protocol for the identification and 
the classification of antigens. It 
could refer to either cell surface 
receptors or ligands.
Glossary
The following textual and web-based sources were consulted: Churchill’s 
Illustrated Medical Dictionary (1989). New York: Churchill Livingstone; Roitt’s 
Essential Immunology (12th edition) (2011). West Sussex: Wiley-Blackwell; 
Immunology: A Short Course (5th edition). Hoboken, NJ: John Wiley & Sons; 
Merriam-Webster (online dictionary), http://www.merriam-webster.com/
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Combination therapy
The use of more than one 
therapeutic approach/medication to 
treat a certain disease.
Crohn’s disease
Chronic disease characterized 
by transmural inflammation 
and deep linear ulceration of the 
distal portion of the ileum (small 
intestine) and/or of the colon.
Cytokine
Class of proteins that modulate 
the function of immune cells; 
immunoregulatory proteins.
Endotoxin
Pathogenic lipopolysaccharide of 
the outer membrane of Gram-
negative bacteria, which can be 
released upon cell lysis.
Fc
The crystallizable, non-




The product of a fusion gene that is 
created through the joining of two 
or more genes that originally coded 
for different proteins; chimeric 
protein.
Helper T cell
Subclass of T cells that recognize 
foreign antigens and secrete 
cytokines that activate other T cells 
and induce B cell proliferation. A 
key category of immune cells in 
regulating immune responses. Also 
known as helper cell or T helper 
cell.
Humanized antibody
Genetically engineered monoclonal 
antibody of non-human (usually 
murine) origin in which all but the 
antigen-binding complementarity 
determining regions’ sequences 
have been replaced with sequences 
derived from human antibodies. 
These antibodies cause lower 
immunogenicity.
Immunogenicity
Ability to induce an immune 
response. 
Immunosuppressive
Ability to suppress natural immune 
responses.
Inflammation
Response to injury caused by 
physical, chemical, or biological 
causes. It serves as a mechanism 
of dilution, containment, and 
destruction of the injurious agent. 
Clinically characterized by redness, 
swelling, pain, heat, and loss of 
function.
Innate immune disease
Disease resulting from dysfunction 
of the innate immune system; an 
autoimmune disease. Not to be 
confused with ‘adaptive immune 
disease’.
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Interferons
Group of cytokines produced by 
immune cells in response to several 
pathogens (particularly viruses) and 
tumour cells. They play a key role 
in immune response regulation.
Interleukins
Leukocyte-secreted cytokine class 
involved in immunoregulation.
Knockout
Term used to describe animals 
that are generated through genetic 
engineering and have a specific 
gene deliberately made non-
functional. The replacement of a 
functional gene with a defective 
(non-functional) copy of the gene 
is an approach used to define in 





Term used to define a molecule 
recognized by (at least) one binding 
molecular structure, such as a 
receptor.
Lymphocytes
Class of leukocytes that are typical 
cellular elements of the lymph 
and that include major cellular 
subclasses of the immune system, 
such as the B and the T cells. 
Lymphoma
Class of tumours that arise from 
lymphatic cells. The two main 
categories of lymphomas are 
Hodgkin and non-Hodgkin 
lymphomas.
Macrophages
Class of leukocytes that undertake 
phagocytosis to destroy foreign 
antigens and serve as antigen-
presenting cells. They derive from 
monocytes and can be found in all 
tissues.
Monoclonal antibodies
Antibodies deriving from a 
single B cell clone, thus being of 
identical antigen-binding sites and 
immunoglobulin isotype.
Monocytes
Class of leukocytes that are 
characterized by a large cytoplasm 
containing a large, smooth, well-
defined, indented, slightly folded, 
oval, kidney-shaped, or notched 
nucleus. They can differentiate into 
macrophages and other leukocyte 
classes.
Mutation
Process of undergoing a permanent 
change in the hereditary material of 
an organism, that could affect the 
functionality of a gene product and 
the organism’s phenotype.
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Placebo-controlled trial
Trial (clinical study) in which a 
group of subjects receives the tested 
treatment, and a separate control 
group receives a sham treatment 
without intrinsic therapeutic value, 
but administered as if it were a 
therapy, i.e. a placebo.
Pre-clinical models
Term referring to in vitro and in 
vivo experimental approaches to 
diseases, taking place as part of 
an efficacy and safety evaluation 
of a drug, prior to its testing on 
humans. If specifically used for in 
vivo experiments, the term reflects 
the appropriate experimental 
setting (either through genetic 
modification and/or disease 
induction) in which an animal can 
be forced to undergo a state that 
closely simulates a (human) disease 
or a representative aspect of it.
Prostaglandins
Unsaturated fatty acids that 
are formed as cyclooxygenase 
metabolites, are composed of a 
chain of 20 carbon atoms, and 
perform a variety of biological 
actions (including the increase 
of vascular permeability, the 
mediation of fever, and the 
modulation of immunological 
responses).
Psoriasis
Chronic disease of the skin 
characterized by well-demarcated, 
red, itchy patches, covered with 
white/silvery scales.
Recombinant (protein)
Protein produced by genetic 
engineering.
Regulatory T cells
Subclass of T cells that regulates 
or suppresses immune responses. 
A key category of immune cells in 
preventing autoimmunity.
Rheumatoid arthritis
Chronic autoimmune disease that 
affects the joints. It is clinically 
characterized by inflammation, 
swelling, stiffness, pain, and (even) 
destruction of joints.
Synovium
Anatomical term for the inner 
layer of the articular capsule of 
the synovial joints. It secretes the 
synovial fluid. Also known as 
synovial membrane.
T cells
Type of lymphocytes that bear 
highly specific cell-surface antigen 
receptors and regulate cell-mediated 
and humoral immunity. They 
mature in the thymus. Also known 
as T-lymphocytes.
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Professor Fran Balkwill 
OBE PhD HonDSc FMedSci (b. 
1952) studied Cellular Pathology 
at the University of Bristol, and 
undertook her PhD on leukaemia 
cell biology in the Medical 
Oncology Department at St 
Bartholomew’s Hospital under the 
late Gordon Hamilton-Fairley. Her 
postdoctoral research was carried 
out in Joyce Taylor-Papadimitriou’s 
laboratory at ICRF Lincoln’s 
Inn Fields (now the Cancer 
Research UK London Research 
Institute), where she began to study 
interferons and their potential 
as cancer therapies. She is now 
Professor of Cancer Biology at Barts 
Cancer Institute, Queen Mary 
University of London (QMUL), 
where she leads the Centre for 
Cancer and Inflammation. She is 
also Co-Research Lead for Queen 
Mary’s Institute of Bioengineering. 
In 2006 she was made a Fellow of 
the Academy of Medical Sciences 
and has served on its Council. 
Fran is also actively involved in 
communication of science to non-
specialist audiences, especially 
young people. Fran is Director of 
the Centre of the Cell, a biomedical 
science centre for children, 
educational website, and outreach 
project in East London. She is also 
a non-parliamentary board member 
of the Parliamentary Office of 
Science and Technology, Chair of 
Understanding Animal Research 
and serves on MRC and European 
Research Council (ERC) grant 
committees. Fran was awarded an 
OBE in the 2008 Queen’s Birthday 
Honours list. In 2015 she was 
awarded the honorary degree of 
Doctor of Science honoris causa by 
the University of Bristol. 
Professor Fionula Brennan
BSc PhD (1957–2012) completed 
her BSc and PhD in immunology 
in Bristol. From 1989 she worked 
with Ravinder Maini and then 
Marc Feldmann, progressing to 
a Professorship in 2001. She was 
very involved in cytokine research, 
co-leading the ‘British Cytokine 
Group’ with Frances Balkwill. 
She was a key participant in the 
discovery of TNF as a therapeutic 
target in RA, and continued to 
contribute to this field.
Professor Yuti Chernajovsky 
PhD FRCP (b. 1954) studied 
biology at the Ben Gurion 
University in Beer Sheva, Israel 
Biographical notes*
* Contributors are asked to supply details; other entries are compiled from conventional 
biographical sources.
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(1976), followed by studies in 
molecular biology at the Weizmann 
Institute of Science Rehovot, Israel. 
He obtained an MSc in 1978 and 
PhD in 1983, during which period 
he cloned and expressed several 
interferon genes. His postdoctoral 
studies were at the ICRF in 
London, and in 1987 he joined 
the faculty of the Immunology 
Department at MD Anderson, 
where he developed gene therapies 
for cancer. At the end of 1990 he 
joined the Kennedy Institute of 
Rheumatology in London where he 
continued to work on gene therapy 
for autoimmune diseases. In 1999 
he was made Arthritis Research 
UK Chair of Rheumatology at 
Barts and The London School of 
Medicine. He retired in 2014 and 
currently serves as consultant to 
a biotech company he founded, 
Stealthyx Therapeutics Ltd. He is 
Emeritus Professor of Molecular 
Medicine at QMUL. 
Professor Jon Cohen
MSc FRCP FRCPE FRCPath 
FFICM FMedSci graduated 
from Charing Cross Medical 
School in 1974 and after house 
officer appointments went to 
Hammersmith Hospital & the 
Royal Postgraduate Medical School 
to begin training in academic 
medicine. He worked initially 
for Professor Sir Keith Peters in 
nephrology, but soon recognized 
that his interests lay in infection 
and particularly in opportunistic 
infection in immunocompromised 
patients. At that time a training 
in academic infectious diseases 
was not available in the UK, so 
he was successful in obtaining a 
Wellcome Trust fellowship to first 
obtain an MSc in microbiology 
at the London School of Hygiene 
& Tropical Medicine and then to 
move to work with Professor David 
Durack in the Infectious Diseases 
Department of Duke University 
in North Carolina. Returning 
to Hammersmith, he set up the 
Department of Infectious Diseases, 
and eventually became Chairman 
of the joint Department of Clinical 
Microbiology & Infectious 
Diseases. In 2002 he was appointed 
as the Foundation Dean of the 
new Brighton & Sussex Medical 
School, eventually stepping down 
in 2013 to take on the role of 
President of the International 
Society for Infectious Diseases. His 
main research interests have been 
in sepsis and septic shock, and 
he has published widely on both 
basic aspects of pathophysiology as 
well as leading major international 
clinical trials of new therapies.
Professor Charles Dinarello
MD (b. 1943) is Professor of 
Medicine and Immunology at the 
University of Colorado School 
of Medicine, and Professor of 
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Experimental Medicine at Radboud 
University in the Netherlands. 
Professor Dinarello received 
his medical degree from Yale 
University and clinical training at 
Massachusetts General Hospital. 
From 1971–1977, he was an 
investigator at the National 
Institutes of Health in Bethesda. 
In 1998, he was elected to the 
United States National Academy of 
Sciences, and in 2011, he became 
a Foreign Member of the Royal 
Netherlands Academy of Arts 
and Sciences. He is a member of 
the Board of Governors of the 
Weizmann Institute (Israel) and 
Ben Gurion University (Israel), 
former Vice President of the 
American Society of Clinical 
Investigation, and was President of 
the International Cytokine Society. 
He has received honarary degrees 
from the University of Marseille 
(France), the Weizmann Institute 
of Science (Israel), the University 
of Frankfurt (Germany), Roosevelt 
University (USA), Albany Medical 
College (USA), Radboud University 
(Netherlands), and Trinity College 
(Ireland). For his contributions 
to the field of cytokines and 
medicine, he received the Squibb 
Award (USA), Ernst Jung Prize 
in Medicine (Germany), Chirone 
Prize (Italian National Academy 
of Medicine), Carol Nachman 
Prize (Germany), Sheikh Hamdan 
bin Rashdid al Madktoum Award 
(United Arab Emirates), Beering 
Prize (USA), Albany Prize in 
Medical Research (USA), Crafoord 
Prize of the Royal Swedish Academy 
of Sciences (Sweden), Paul Ehrlich 
Prize (Germany), Bonfils-Stanton 
Prize (USA), the Novartis Prize in 
Clinical Immunology (Switzerland), 
and the Bonazinga Award (USA).
Professor Sir Marc Feldmann
Kt AC FMedSci FRS (b. 1944) 
graduated in medicine at the 
University of Melbourne, before 
taking a PhD at the Walter & Eliza 
Hall Institute studying in vitro 
immune responses and immune 
regulation with Sir Gustav Nossal. 
He undertook postdoctoral research 
(1972) with Avrion Mitchison at 
the ICRF Tumour Immunology 
Unit, which led to the generation 
(1983) of a new hypothesis for 
the mechanism of autoimmunity. 
Testing this idea led him to leave 
ICRF and move to the Kennedy 
Institute of Rheumatology. There, 
with Maini and Brennan, TNF 
was defined systematically as a 
therapeutic target for RA, and, 
together with Maini, he led clinical 
trials to verify this concept in 
patients. This work has led to 
much recognition, election to 
Academies of Science in Australia, 
USA, and the UK (Royal Society 
and Academy of Medical Sciences), 
as well as to major research prizes 
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shared with Ravinder Maini, 
including the Crafoord Prize of the 
Royal Swedish Academy (2000), 
the Albert Lasker Clinical Research 
Award (2003), the Paul Janssen 
Prize (2008), the Ernst Schering 
Prize (2010), and the Canada 
Gairdner Award (2014). Feldmann 
was also ‘European Inventor of the 
Year’ in the ‘Lifetime Achievement’ 
category in 2007. Knighted 
in 2010, he also received the 
Australian equivalent ‘Companion 
of the Order of Australia’ in 2014.
Professor Walter Fiers
PhD (b. 1931) obtained a degree 
of Engineer for Chemistry and 
Agricultural Industries at the 
University of Ghent (1954) and 
then started his research career as an 
enzymologist in the laboratory of 
Laurent Vandendriessche in Ghent. 
He then worked in Copenhagen 
before obtaining a fellowship from 
the Rockefeller Foundation and 
joining molecular biologist Bob 
Sinsheimer’s group at the California 
Institute of Technology as a postdoc 
in 1960. In 1962, he moved to 
Madison, Wisconsin, to work in 
the laboratory of future Nobel 
laureate, Gobind Khorana. At the 
end of 1962, Dr Fiers set up the 
Laboratory of Molecular Biology 
at the University of Ghent. His 
research led to his participation 
in the development of a new 
discipline that later evolved into 
‘recombinant DNA technology’. Dr 
Fiers and his colleagues managed in 
1980 to clone and express the gene 
coding for human IFN-β and, later, 
of IL-2, IFN-γ, and TNF. In 1997 
he retired and became Professor 
Emeritus, and the following year he 
retired from his position as Director 
of the Laboratory. 
Professor Joachim Kalden 
MD PD (b. 1937) studied 
medicine at the University of 
Tübingen. He was a research 
fellow at the Department of 
Therapeutics and the MRCs 
Clinical Endocrinology Unit at 
the University of Edinburgh from 
1967 to 1970. He undertook his 
habilitation at the Department 
of Internal Medicine, Hannover 
Medical School, where he was also 
an assistant in the Department for 
Internal Medicine, and became a 
Privatdozent in 1973. From 1974 to 
1976 he was Consultant Physician 
in the Department for Internal 
Medicine, Clinical Immunology 
and Rheumatology at Hannover. 
In 1977 he was appointed Director 
of the Department of Internal 
Medicine III and Institute for 
Clinical Immunology, in which 
post he remained until his 
retirement in 2006, then becoming 
Director Emeritus. His major 
research interests over the years 
have been in the pathogenesis of 
rheumatic diseases, with emphasis 
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on SLE and RA, including the 
development of new therapeutic 
principles. He was President of 
EULAR from 2001 to 2003, and 
he has been an active member of 
many national and international 
scientific boards and committees 
(including the Chairmanship of 
the EULAR Standing Committee 
for Clinical Trials) and has served 
as Chairman of the World Health 
Organization/International Union 
of Immunological Societies 
Standardization Committee. He 
was a Member of the Senate of 
the German Academy of Science 
and he is also a Member of the 
Bavarian Academy of Science. 
He was awarded the honorary 
degree of Doctor of Medicine 
honoris causa by the University 
of Berlin in 1998, the University 
of Lund in 2005, and by the 
Hannover Medical School in 2013. 
Among numerous awards are 
the International Rheumatology 
Award of the Japanese College for 
Rheumatology in 2005 and the 
AESKU prize for Life Contribution 
to Autoimmunity, Sorrento, Italy in 
2006. He has published more than 
600 articles. 
Professor Sir Ravinder Nath 
(Tiny) Maini 
Kt FRS FMedSci FRCP MB BChir 
(b. 1937) studied medicine at 
Cambridge University and Guy’s 
Hospital London, graduating in 
1962. He undertook postgraduate 
clinical training and a fellowship in 
clinical immunology in London. 
In 1970 he was appointed 
Consultant Physician at Charing 
Cross Hospital, and since then he 
combined practice as a clinician 
in rheumatology and internal 
medicine with laboratory-
based immunological research 
at the Kennedy Institute of 
Rheumatology. He was appointed 
Professor of Immunology at 
Charing Cross Medical School in 
1979, and from 1990 to 2002 he 
was Professor of Rheumatology 
and Scientific Director/Head 
of the Kennedy Institute of 
Rheumatology, at Imperial College, 
London, until his retirement. His 
‘bench to bedside’ research, in 
collaboration with Marc Feldmann, 
which commenced in 1985, has 
resulted in the development of 
anti-TNF immunotherapy of RA. 
Following the identification of 
TNF as a therapeutic target and 
translation of anti-TNF therapy 
to the clinic, Professors Maini 
and Feldmann have been jointly 
awarded many prizes, notably 
the Crafoord Prize by the Royal 
Swedish Academy of Sciences, the 
Lasker Prize for Clinical Research, 
the Dr Paul Janssen Award for 
Biomedical Research, the Ernst 
Schering Prize, and the Canada 
Gairdner International Award. He 
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has been Emeritus Professor of 
Rheumatology at Imperial College, 
London since 2002, and a Visiting 
Professor to the Kennedy Institute 
of Rheumatology at Oxford. 
Professor Jeremy Saklatvala 
BSc MBBS PhD FRCP FMedSci 
(b. 1943) qualified in medicine 
at University College Hospital 
London in 1968, specialized in 
Rheumatology at the MRC unit at 
the Canadian Red Cross Hospital at 
Taplow (UK) and in Glasgow at the 
Centre for Rheumatic Diseases. He 
obtained his PhD in Biochemistry 
on plasma protease inhibitors in 
1975 at Strathclyde University, and 
was subsequently Arthritis Research 
Campaign Senior Research Fellow 
at Strangeways Research Laboratory 
in Cambridge working on the early 
characterization and purification 
of IL-1 and its role in cartilage and 
bone destruction. He also identified 
the similar actions of TNF and 
the common IL-1 receptor. He 
moved to the Babraham Research 
Institute in 1993 and focused on 
intracellular signalling mechanisms 
of IL-1 and TNF, particularly 
discovering the p38 MAPK 
pathway. He moved to the Kennedy 
Institute of Rheumatology in 
London in 1996, retiring as Deputy 
Director in 2014 following the 
move of the Kennedy Institute to 
be part of the University of Oxford 
in 2013.
Professor Josef Smolen
MD FRCP graduated from the 
Medical Faculty of University of 
Vienna, and trained at the Institute 
of Immunology, University of 
Vienna, under Carl Steffen. He 
undertook his residency in Internal 
Medicine at the 2nd Department of 
Medicine under Georg Geyer, and 
performed a research fellowship at 
the National Institutes of Health, 
National Institute of Arthritis, 
Diabetes and Digestive and Kidney 
Diseases, Arthritis and Rheumatism 
Branch (headed by John Decker) 
in the Section for Cellular 
Immunology under Alfred D. 
Steinberg. He is now Professor of 
Internal Medicine and Chairman of 
the Division of Rheumatology and 
Department of Medicine 3 at the 
Medical University of Vienna. He is 
also Head of the 2nd Department 
of Medicine – Center of Rheumatic 
Diseases at Hietzing Hospital, 
Vienna. Professor Smolen has 
served as President of the EULAR 
(2003–2005), as President of the 
Austrian Society of Rheumatology 
(2005–2007), and as President 
of the Austrian Society of 
Immunology (2007–2009). Since 
2003 he has been a Member of the 
Austrian Academy of Sciences and 
since 2007 of the German Academy 
of Sciences. He became a Fellow of 
the Royal Society of Physicians in 
2008 and Honorary Doctor of the 
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University of Lund in 2010. He is 
Editorial Board Member of several 
professional journals and has edited 
textbooks and handbooks in the 
field of rheumatology.
Professor Tilli Tansey 
OBE PhD PhD DSc HonMD 
HonFRCP FMedSci (b. 1953) 
graduated in zoology from the 
University of Sheffield in 1974, 
and obtained her PhD in Octopus 
neurochemistry in 1978. She 
worked as a neuroscientist in the 
Stazione Zoologica Naples, the 
Marine Laboratory in Plymouth, 
the MRC Brain Metabolism Unit, 
Edinburgh, and was a Multiple 
Sclerosis Society Research Fellow 
at St Thomas’ Hospital, London 
(1983–1986). After a short 
sabbatical break at the Wellcome 
Institute for the History of 
Medicine (WIHM), she took a 
second PhD in medical history 
on the career of Sir Henry Dale, 
and became a member of the 
academic staff of the WIHM, later 
the Wellcome Trust Centre for the 
History of Medicine at UCL. She 
became Professor of the History of 
Modern Medical Sciences at UCL 
in 2007 and moved to QMUL, 
with the same title, in 2010. With 
the late Sir Christopher Booth she 
created the History of Twentieth 
Century Medicine Group in the 
early 1990s, now the History of 
Modern Biomedicine Research 
Group at QMUL.
Dr Marcos Vidal
PhD (1974–2016) graduated 
in biology from the National 
University of Rosario (UNR), 
Argentina, and obtained a PhD 
in vitamin D metabolism in 
macrophages at the UNR in 2003. 
He undertook his postdoctoral 
studies in the laboratories of Ross 
Cagan in Washington University 
in Saint Louis (2003–2007) and 
in Mount Sinai Medical School 
(2007–2009), where his research 
focused on oncogenic kinases in 
Drosophila models for cancer. In 
2009 he started a group leader 
position at the Cancer Research 
UK Beatson Institute in Glasgow to 
study tumour-immune interactions 
in Drosophila. He was also elected 
a member of the Royal Society 
of Scotland Young Academy 
of Scotland. In recognition of 
his work and standing in the 
field, in July 2015, Dr Vidal was 
unanimously recommended for 
promotion to Senior Group Leader 
by a panel of external experts, and 
was also subsequently promoted 
to Professor at the University of 
Glasgow.
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Professor Henning Walczak
MSc PhD (b. 1966) graduated 
in biology from the University of 
Bielefeld in 1992, and obtained a 
PhD from the same university in 
1995 for work carried out at the 
German Cancer Research Centre 
(DKFZ, Heidelberg, Germany) on 
activation-induced T cell death. He 
worked at Immunex Corporation 
in Seattle (WA, USA) for two years 
(1996–1997) before returning to 
DKFZ in 1998, where he became 
Group Leader in 2000 following 
receipt of a BioFuture Prize 
awarded by the German Ministry 
for Science and Education. In 
2007 he was appointed Chair of 
Tumour Immunology at Imperial 
College London, joining UCL’s 
Cancer Institute in 2013 where 
he currently acts as Head of the 
Department & Chair of Cancer 
Biology and Scientific Director of 
the Cancer Research UK – UCL 
Centre. In 2012 he was awarded 
both an ERC Advanced Grant 
and a Wellcome Trust Senior 
Investigator Award. His research 
focuses on cell death and ubiquitin 
in inflammation, cancer, and 
(auto)immunity. He is particularly 
interested in unravelling the 
mechanisms of how the TNF, 
CD95, and TRAIL death receptor-
ligand systems, but also other 
TNF superfamily receptor-ligand 
systems, are regulated and how they 
impact cancer cell survival, cancer-
related inflammation, and cancer 
immunity.
Associate Professor Richard 
Williams
BSc MSc PhD (b. 1956) 
graduated in agriculture at the 
University of Wales, Bangor, in 
1979, and obtained an MSc in 
animal parasitology in the same 
institution in 1981. He worked 
briefly with R. S. (Bill) Bray 
at Imperial College at Silwood 
Park, Ascot, on immunity to 
leishmaniasis (1984–1985) before 
joining the Babraham Institute 
to work with Tony Whyte on the 
immunotherapy of RA. In 1989 
he moved to the Kennedy Institute 
of Rheumatology in London to 
work as a research assistant with 
David Williams before obtaining 
a PhD in immunology in 1995 at 
the University of London under 
the supervision of Tiny Maini. His 
work with animal models played an 
important role in the development 
of TNFα blockade as a therapeutic 
strategy for RA and since then he 
has continued to do translational 
research. In 2000 the Kennedy 
Institute of Rheumatology was 
incorporated into Imperial College 
London and Richard Williams 
was appointed as Senior Lecturer 
in 2007, and then promoted to 
Reader in 2010. The Kennedy 
Institute joined the University 
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of Oxford in 2011 and he was 
appointed as PI and Associate 
Professor in 2014.
Dr James (Jim) Woody 
MD PhD is a General Partner of 
Latterell Venture Partners, a venture 
capital firm that invests in early 
and late stage biopharmaceutical, 
instrumentation, and medical 
device companies, since November 
2005. Dr Woody brings more than 
25 years of biomedical research 
and management experience to 
the partnership. He was formerly 
President of Roche Bioscience 
(former Syntex) in Palo Alto, 
California (1996–2004), where he 
had responsibility for bioscience 
research and clinical development. 
Previously, Dr Woody served 
as Chief Scientific Officer and 
Senior Vice President of R&D for 
Centocor, now Janssen Biotech 
(1991–1996). While at Centocor, 
Dr Woody, along with colleagues, 
developed ‘Remicade’, the first 
of the TNF inhibitor biologics, 
the first effective therapy for RA, 
Crohn’s disease, and psoriasis. Prior 
to Centocor, Dr Woody served 
as a US Navy Medical Officer, 
was the cofounder with Navy 
colleagues of the National Marrow 
Donor Program. He retired as 
Commanding Officer and Director, 
US Naval Medical Research and 
Development Command in 
Bethesda, Maryland. Dr Woody 
currently serves as a member of 
the board of directors of four LVP 
companies, and was the founding 
CEO and Chairman of the Board 
of OncoMed Pharmaceuticals, 
Inc. (2004–2014) (IPO with 
NASDAQ: OMED 2013). Dr 
Woody is a member of the Board 
of Directors of the Lucille Packard 
(Stanford) Children’s Hospital 
(LPCH) in Palo Alto, California. 
He holds an MD from Loma Linda 
University, trained in Pediatric 
Immunology at Duke University 
and Boston Children’s Hospital 
(Harvard University), and earned 
a PhD in Immunology from the 
University of London, England. 
Dr Woody has authored or co-
authored over 140 publications.
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